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Abstract: A large body of evidence indicates that three dimensional (3D) cancer models are superior to two-dimensional 
(2D) ones in better representing the in vivo phenomena. Indeed, 3D models allow recapitulating in vitro the in vivo 
features observed in solid tumors (e.g. cell polarity, cell-cell/cell-matrix interactions, biochemical/metabolic gradients, 
anchorage-independent growth and hypoxia). Moreover, it is well established that the microenvironment plays a 
fundamental role in regulating tumor development and behavior, including drug resistance. Thus, innovative models able 
to mimic this complexity represent attractive tools in cancer research. In this review article, we provide a comprehensive 
review of the application of 3D culture systems in pediatrics’ cancer research. In particular, 3D in vitro/ex vivo models of 
the most common pediatric tumors, such as leukemias, lymphomas and malignancies of the nervous system, will be 
considered.  
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1. INTRODUCTION 
For almost all cancers, if death rates continue to 
decline, statistics indicate that the number of new 
cases/year and the number of mortality deaths are still 
too high. In 2014, in effect, the estimate of cancer 
incidence in the USA will be about 1.66 million new 
cases, while deaths will reach the number of 585.720 
patients [1]. In Europe (2012), the predicted number of 
new cases of cancer was 3.45 million, and 1.75 million 
deaths [2], while, for 2013, the predicted number of 
cancer deaths decreased to 1.31 million [3]. For 
children and adolescents (birth to 19 years old) in USA, 
for 2014, the predicted number of newly diagnosed 
cases of cancer is 15,780 and about 1,960 deaths from 
cancer will occur. The annual incidence rate of cancer 
for this young population is 186.6 per 1 million [4]. 
Altogether, these data demonstrate that we are far 
away from assuring the cure of cancer patients. 
Tumorigenesis is a multistep process, and it was 
initially considered as a succession of mutations 
occurring in oncogenes, in tumor suppressors and, 
ultimately, in microRNAs, all events which lead to a 
successive uncontrolled proliferation of tumor cells, 
induction of angiogenesis and lymphangiogenesis, and 
further metastatic processes [5]. The high hetero- 
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geneity of cancers between individuals is thought to be 
multifactorial due to genetic diversity, the presence of 
cancer stem cells, and the impact of the tumor 
microenvironment [6]. It is well-known that genotypic 
alterations alone are not sufficient to explain tumor 
progression and metastatic processes, and that the 
tumor microenvironment can be profoundly involved in 
regulating tumor growth, local invasion of the stroma, 
angiogenesis/lymphangiogenesis, intra/extravasation, 
metastasis, drug resistance, as well as tumor reversion 
[7-11]. 
In the present review, we have considered the 
concept of the tumor microenvironment in adult solid 
neoplasms and in the in vitro models available to study 
the main hallmarks of adults’ cancer, and childhood 
malignancies. There are some differences between 
adults’ and childhood’s tumors; for example, the 
incidence of tumor types is different. In adults, 
carcinomas/solid tumors are the most frequent types of 
neoplasms (about 80%), whereas in childrens/ 
adolescents, leukemia accounts for about the 30% of 
the total tumors, followed by malignancies of the 
Central Nervous System (CNS) (20-25%), by 
lymphomas (16%) and neuroblastomas (7.6%) [12]. In 
adults, parenchymal cells are mature and terminally 
differentiated, and then only a limited number of cells 
highly proliferate, whereas in young people (and mostly 
in children), a certain number of organs/tissues present 
an incomplete terminal maturation, and their cells, 
instead of differentiating, continue to proliferate and 
die. This increases the difficulty of chemotherapeutic 
Tissue-Specific 3D Microenvironments and Possibile Application to Pediatric Cancer Research Journal of Pediatric Oncology, 2014, Vol. 2, No. 1      41 
treatment of the tumor’s proliferating cells without side 
effects on healthy tissues. Finally, in children, tumors 
may require quite a few events to progress, as 
compared to the adult ones [13]. In the last section of 
the review we have illustrated and discussed specific 
3D cell-based systems suitable for modeling the most 
common pediatric tumors, such as leukemias, 
lymphomas, CNS’s cancers and neuroblastoma. 
2. THE IMPORTANCE OF THE TUMOR 
MICROENVIRONMENT 
The normal tissue’s microenvironment is 
characterized by specific architecture, extracellular 
matrix (ECM) and parenchymal cell types, as well as by 
the presence of vasculature, immune cells, and specific 
physical and biochemical cues (e.g. interstitial 
pressure, biomechanical factors, cell metabolism’s 
 
Figure 1: The stroma microenvironment is an active contributor to tissue homeostasis and pathology. Microenvironment 
exerts a selective pressure onto tumor cells, as well as tumor cells that interact with the microenvironment may selectively 
constraint it to progress toward tumorigenic process or to regress to “normal” state.  
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products, anti-oxidative agents, gas components, pH). 
Tissue homeostasis results from the balance between 
cell-cell/cell-matrix interactions and from the 
composition and organization of the stroma. Alterations 
of cell (normal versus malignant) or/and microenviron-
ment stability/features can result either in the malignant 
phenotype reversion or in tumor growth (Figure 1). In 
such reversible configurations, the cell microenviron-
ment is often proposed as a “tumor suppressor” 
element, since it is thought to limit cancer progression. 
Different cellular and macromolecular entities are 
implicated in tumor suppression (e.g. immune, 
epithelial, or myoepithelial cells, proteases, junctions 
such as desmosomes) [9, 14-16]. Drugs such as 
tamoxifen can also suppress the tumor phenotype by 
interfering with the mammary ECM [17]. On the other 
hand, when the microenvironment is modified, its 
composition/architecture varies, in such a way that it 
becomes more permissive to tumor growth, and begins 
to play a crucial role in regulating tumor evolution and 
propagation. In the pre-tumor/tumor microenvironment, 
it is really possible to observe a loss of tissue 
architecture, aberrant cells and ECM (in quality and 
quantity, desmoplasia), neoangiogenesis/lymphangio-
genesis, inflammatory and fibrotic processes, 
recruitments of tumor-associated fibroblasts and 
macrophages, infiltration of leukocytes, high presence 
of cytokines, growth factors, hormones, morphogens 
and proteolytic enzymes. Tumor cells and inflammation 
are often intimately co-involved in the further tumor 
development. Indeed it is well-known that the local 
inflammatory tumor microenvironment has an impact 
on cancer development; its role is so fundamental to 
tumor progression that it now represents a hallmark of 
cancer [6]. Moreover, recent findings have 
demonstrated that tumors can affect distant tissues, by 
inducing a chronic inflammatory response in vivo, 
leading to increased systemic levels of oxidative DNA 
damage [18]. The stroma itself may possess an 
oncogenic impact, independently of the presence of 
tumor cells [19]. Moreover, the tumor microenvironment 
is also involved in the drug resistance process that it is 
an important cause of cancers’relapse and fatal onset. 
The components of the tumor microenvironment 
vary according to the tumor type, but usually two main 
compartments can be identified: i) the cellular 
compartment consisting of tissue specific cells 
(fibroblasts, pericytes, smooth muscle cells, endothelial 
cells, mesenchymal cells, immune and/or inflammatory 
cells) and ii) the matrix-related compartment 
comprising a solid phase (extracellular matrix) and a 
more “fluid-phase” (soluble factors: cytokines, 
chemokines, trophic factors). There is a dynamic 
interplay between tumor cells, normal cells and their 
surrounding matrix that involves biomechanical and 
biochemical signals, integrated into complex molecular 
interactions and intra- and extracellular signaling 
networks [20], outlined in Figure 2. 
2.1. The Main Cellular Actors in the Host Stroma 
2.1.1. The Non Malignant Cell Compartment 
The reciprocal interactions between malignant cells 
and their neighboring host stromal cells actively 
regulate tumor features, growth, invasion, angiogenesis 
and metastasis. These interactions can also be 
mediated by paracrine factors. Moreover, tumor cells 
recruit/activate non-malignant cells (bone marrow-
derived cells, inflammatory and immune cells, cancer 
associated fibroblasts, pericytes, endothelial cells), 
which interfere with the normal, physiologic micro-
environment. The (abnormal) tumor microenvironment 
itself favors tumor progression by altering cell function 
and ECM cues. 
Bone marrow derived Mesenchymal stem cells 
(MSCs) present an innate tropism for tumor [21] as a 
result of tumor cells’ chemotaxis, mediated, for 
example, by growth factors (VEGF, EGF, HGF, bFGF 
and PDGF). The MSCs homing can also be regulated 
by chemokines and proteases (urokinase, 
metalloproteases). MSCs can be recruited by tumor 
cells, and when they reach the tumor micro-
environment, they differentiate in tumor-associated 
fibroblasts, pericytes and myofibroblasts [22-23]. 
Reciprocally, these mesenchymal cells can attract 
tumor cells in the bone marrow district. Their exact role 
as tumor suppressor or promoter is still in discussion 
because of the complexity of their intercellular and 
molecular interactions with the tumor microenvironment 
[24]. 
Inflammatory cells. Chronic inflammation are 
recognized as an important step in cancer progression 
[25]. The inflammatory infiltration in tumors results from 
the recruitments of leukocytes mediated by cytokines 
and chemokines synthesized by malignant cells. This 
process is important for the further angiogenic process. 
Inflammatory and immune response is intimately linked 
in determining tumor behavior.  
Immune cells. Among all functions of the immune 
system, the immune-surveillance should, as a rule, also 
eliminate cancer cells. Cells dedicated to such targets 
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are mainly lymphocytes T, monocytes/macrophages, 
mast cells and natural killers (NK). However, in addition 
to preventing tumor growth, the immune system is 
involved in the opposite induction of cell transformation 
(tumorigenesis), the so called process of cancer 
immune-editing [26]. A way by which immune cells can 
promote tumorigenesis is the increase in MMP 
synthesis, involved in ECM remodeling and, therefore, 
in the remolding of the stromal microenvironment [27]. 
Tumor Associated Macrophages (TAMs). TAMs 
are present in many tumors as a significant cell 
population; moreover their high number also 
corresponds to a poor prognosis’ marker in many 
 
Figure 2: The main cancer hallmarks. The heterogeneous tumor microenvironment embraces a cohort of cells (stromal cells, 
immune and inflammatory, stem cells, etc.), gradients of bioactive molecules, macromolecular, biophysical and biochemical 
cues (ECM, growth factors, cytokines, metabolites), which allow interactions and resulting signaling networks to contribute to 
tumor progression. Whereas normal cells and ECM may be conducive to tissue homeostasis and tumor phenotype reversion, 
the tumor microenvironment leads to a cascade of events that usually finishes with the dissemination of tumor derived cells into 
other tissue districts of the body. These changes regard either cells behaviors and features (for example switching from normal 
fibroblasts or myoepithelial and epithelial cells to myofibroblasts, cancer associated fibroblasts, mesenchymal cells etc) or 
activation of an adaptive response by altering cell metabolism and syntheses (from oxidative to glycolytic pathways) as well as 
gene expression (hypoxia inducible factor 1 (HIF-1), proteases, integrins, cadherins, growth factor, cytokines, chemokines, pro-
angiogenic morphogens), due to hypoxic and acidic environment and resulting in ECM remodeling, basal membrane collapse, 
activation of angiogenesis/lymphangiogenesis and subsequent migratory/metastatic processes to target organs. Tumor and 
tumor microenvironment characteristics vary between cancer types, patients and in the course of the pathology. For leukemia, 
for example, osteoblastic/endosteal and hematopoietic stem cells niches, in addition to the cohort of cells already described, 
play a crucial role.  
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cancers. Monocytes are recruited into the tumor by 
chemotaxis (mainly by chemokines and factors such as 
CCL2, CCL-5, CCL8, CXCL-12, VEGF, MIP1a, and 
MIF). Macrophages can produce VEGF-C and VEGF-
D, MMP-2 and IL-8, playing, by this way, an important 
role in lymphangiogenesis and ulterior metastatic 
processes mediated by the lymphatic system. They can 
also produce a number of angiogenic growth factors, 
cytokines and proteases, which are implicated in tumor 
progression. Macrophages also interact with tumor 
cells, reciprocally exchanging/sensing biochemical 
cues (mediated by CXCL-12 and EGF or NO and 
CXCL-12) [28, 29]. 
Dendritic cells. These cells are physiologically 
involved in the innate and adaptive responses of the 
immune system. Moreover, they are recruited in the 
tumor environment regulate the angiogenic process by 
secreting TNF?, TGF?, GM-CSF and IL-12 [30]. 
Whereas they can play a crucial role in inhibiting tumor 
growth, their normal activities and maturation can be 
hindered by tumor associated macrophages, reducing 
in such a way the immune surveillance necessary to 
counteract tumor growth [31-32]. The capability of this 
cell type to regulate angiogenesis might also be linked 
to their predisposition to differentiate into endothelial-
like cells in response to tumor signals [33]. Moreover, 
because they also secrete metalloproteases (MMPs) 
and their inhibitors (TIMP), they can play a role in 
tumor progression and metastasis [34]. Mast cells are 
immune cells involved in immunological and 
inflammatory responses. They can either down 
regulate the tumorigenic process by secreting 
interleukins, or promote tumor growth by interfering 
with stroma-epithelium interaction and ECM 
degradation, encouraging angiogenesis (e.g. by 
secreting factors such as VEGF, FGF-2 and IL8) and 
lymphangiogenesis, and inhibiting antitumor activity 
[10, 35]. 
Cancer-associated fibroblasts. Within a tumor 
mass, different types of sub-populations of fibroblasts 
are usually found (i.e. dormant fibroblasts, 
myofibroblasts, cancer-associated fibroblasts), that are 
molecularly different from their normal fibroblastic 
counterparts [36]. They synthesize great amounts of 
ECM components (type I collagen and fibronectin) and 
are largely responsible for desmoplasia. These 
abnormal fibroblasts secrete matrix proteases and 
relative inhibitors (whose crucial role is either linked to 
their proteases’ activity, or to their non-proteolytic 
activity), which are paracrine factors that regulate 
tumor growth (EGF, TGF?, HGF, PDGF, IL1, IL6, IL8), 
as well as angiogenesis (VEGFA and FGF) [37]. 
Cancer-associated fibroblasts produce CXCL12 that 
allow the recruitment of endothelial progenitors from 
the bone marrow [38]. These fibroblastic cells originate 
mainly from the trans-differentiation of resident 
fibroblasts, but also from bone marrow mesenchymal 
cells [36]. One part of these cells probably also derived 
from the epithelial-mesenchymal transition (EMT) that 
takes place during tumor invasion. Cancer-associated 
fibroblasts represent a noticeable part of the tumor 
mass and influence tumorigenesis (initiation, 
progression, invasive and metastatic processes) [9, 
39]. They sustain cancer cells’ survival by removing 
their metabolic wastes [40], and their presence also 
represents an unfavorable parameter for cancer 
patients [41]. 
Adipocytes - cancer associated adipocytes. 
These cells are responsible for energy storing, and can 
directly provide lipids to tumor cells; adipocytes also 
play an important role in regulating the tissue 
microenvironment, because of their capacity to 
synthesize a number of biologically active molecules, 
referred to as adipokines, and which include cytokines, 
growth factors, hormone-like factors and chemokines 
[42]. These tumor-associated adipocytes were shown 
to promote the growth of malignant tumors in breast, 
colon and prostate tissues) [43-45]. Moreover, adipose 
stromal cells might also be recruited in the tumor 
microenvironment and contribute to the differentiation 
of progenitors into pericytes and adipocytes [46]. 
Tumor associated endothelial cells. These cells 
are involved in the angiogenic process that promotes 
cancer progression. Moreover, the hypoxic 
environment within the tumor’s tissue, together with 
neoplastic, stromal and inflammatory cells secreting 
VEGF, stimulate the angiogenic switch of quiescent 
endothelial cells to proliferating cells. This leads to the 
building of a new, abnormal architecture and poorly 
functional blood vessels [47, 48], that fail to become 
quiescent because they lost the adequate control of 
pro- and anti-angiogenic factors. Besides, these neo-
endothelial cells synthesize growth factors favoring 
tumor (IGF, PDGF, GM-CSF). 
Perycites. The recruitment of pericytes into the 
tumor’s microenvironment is mediated by PDGF-B 
receptor expression [49]. These cells participate in the 
maintenance of functional vessels, while their reduced 
number in tumor’s vessels seem to sustain 
intravasation processes.  
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2.1.2. The Malignant Cell Compartment 
The hypothesis of Cancer stem cells (CSCs) 
existence is based on tumor’s heterogeneity; more 
recent evidence seems to indicate that these tumor 
cells’ subsets might be liable to tumor progression [50, 
51]. Their presence was shown in leukemia as wells as 
in solid tumors, even if at a lesser level [52, 53]. The 
hypotheses regarding their origin are still under 
investigation [50]. The heterogeneity in CSCs’ (and in 
their progeny’s) phenotype and function between 
patients and tumor’s type, as well as inside the same 
individual tumor, increases the difficulty in better 
characterizing them and targeting them for therapy. 
Moreover, these cells might be present in a pre-
metastatic niche, either as Epithelial to Mesenchymal 
Transition (EMT) derived cells, or as a trigger for the 
recruitment of metastatic cells in a hospitable niche 
[52]. 
All the host cells are, at the beginning, without 
apparent malignant properties, but, probably due to the 
wrong microenvironment pressure, to their dynamic 
intercellular interactions, and to their active 
communication with tumor cells, they express an 
atypical phenotype [54]. 
2.2. ECM Compartment 
The ECM, in addition to representing a support 
structure for cells, is also responsible for regulating vital 
biological processes (such as differentiation, prolifera-
tion, viability, migration, cell interactions/communica-
tion), and serves as reservoir for a number of factors. 
Matrix properties that are directly involved in the 
regulation of such events are: i) its own biochemical 
composition (e.g. collagen, laminin, fibronectin, 
tenascin C, hyaluronic acid (HA), proteoglycans, 
cadherins, integrins, osteopontin, galectins, fibulin-1), 
ii) the presence of matrix proteases involved in ECM 
remodeling/breakdown (MMPS, urokinase plasminogen 
activators, cathepsins), iii) its organization (at macro-, 
micro- and nanoscale), or iv) its capacity to interact 
with biologically active molecules (growth factors, 
cytokines, chemokines), usually stored for interacting 
with ECM macromolecules, and also v) its biomechani-
cal properties, that are directly linked to the regulation 
of gene expression. MMPs are enzymes involved in 
ECM turnover, and, in such a way, within the tumor 
context, they play a noticeable role as regulators of 
tumor progression [34, 55]. ECM also presents 
mechanical properties (stiffness, compliance) that 
regulate cell behavior, owing to mechanotransduction 
pathways and mechanosensing cell capacities. These 
ECM characteristics influence (prevent or favor) tumor 
invasion, as a consequence of alterations in tensegrity, 
namely in the equilibrium in continuous tension and 
discontinuous compression forces existing at the 
matrix, cell, and intracellular levels and that stabilizes 
cell functions [56-58]. Alterations in ECM stiffness/ 
compliance were shown, for example, in murine breast 
where: in normal murine breast elastic modulus is 
about 170 Pa, in the tumor surrounding stroma it 
increases up to 920 Pa whereas it reaches about 4000 
Pa in tumor [59]. 
Integrins function as mechano-transducers and 
influence gene expression and cell behavior. Integrins 
show a crucial, and often contradictory, role on 
regulation cell migration, invasion, proliferation and 
survival; they orchestrate host cells’ behavior and thus 
tumor progression [59-61]. The integrin subtypes that 
are more frequently overexpressed in tumors are, for 
example, ?v?3, ?v?5, ?5?1,  ?4?1, ?v?6 and ?6?4. The 
expression and clustering of integrins in turn can be 
modulated by the ECM stiffness, resulting in a more 
tumorigenic phenotype [59]. In addition to the tissue 
architecture stability, the matrix integrity is fundamental 
too and regulates the release of pro and antiangiogenic 
cues, by mean of its type IV collagen, fibronectin and 
thrombospondin-1 components [62, 63]. In effect, when 
ECM proteins are hydrolyzed by matrix proteolytic 
enzymes, pro- and anti-angiogenic factors, and other 
ECM-sequestered factors, turn out to be bioavailable 
[62, 64]. 
Tumor microenvironment was shown to be also 
involved in drug resistance. Resistance to chemothera-
peutics may be determined by tissue organization, cell 
adhesions/interactions, ECM viscosity (and relative 
drug diffusion in the interstitial space), hypoxic and 
acidic intratumoral context, or by soluble mediators 
produced by tumor, host cells and their cross-talk [8, 9]. 
Another factor that points to the importance of the 
microenvironment in tumor progression is evinced in 
the appearance of second cancers after radiotherapy. 
Radiotherapies may have opposite effects on the 
tumor: whereas they locally present the expected anti-
tumor effect, they can also alter the tumor 
microenvironment (increase in growth factors’, 
cytokines’ or tumor promoting factors’ secretion), and 
might contribute, in such a way, to local invasion and 
metastatic processes in pre-irradiated zones [65]. This 
was confirmed by several observations, which 
suggests that the effect of radiation depends on a 
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number of parameters (the characteristics of the 
irradiated tissue, the age of the patient, the dose and 
dose rate, the volume of targeted tissue, and hereditary 
factors) [66]. The effects of radiation might be mediated 
by genomic instability of cells that survive to the 
therapy, by the selection of hypoxic resistant cells, by 
the activation of the tumor microenvironment’s 
production of growth factors and proteases, as well as 
by the possible radio-resistance of a subset of cancer 
stem cells [67]. 
3. DEVELOPING MORE BIOMIMETIC CANCER 
MODELS 
In order to overcome the high incidence of tumors, 
to increase the efficacy of treatments (in addition to 
traditional surgery, chemotherapy and radiotherapy), 
and to reduce therapy-related side-effects and 
resistance, it is necessary that oncology research 
points to the development of new therapeutic 
strategies, (such as, for example, specific immuno-
therapy and molecular-targeted therapy), in order to 
better focus onto specific molecular/microenviron-
mental objectives [68]. This will, further, provide a more 
specific patient-targeted therapy, as tumorigenesis 
reflects a complex and heterogeneous situation, closely 
related also to individual characteristics. Unfortunately, 
whereas in preclinical studies alternative strategies 
were shown to be efficient, when translated to patient’s 
treatment, they often showed an unsuccessful 
outcome. This may be due to the “gap” still existing 
between in vivo (animal-based) models (immuno-
compromised or transgenic/humanised mice), in vitro/ 
ex vivo culture models, and in humans (i.e. clinical 
application); thus, the lack of physiologically relevant 
models for the study of human tissues’ functions and 
behavior is now well recognized, at the different levels 
of basic and applied research and risk assessment 
[69]. Moreover, in addition to ethical reasons, the 
application of the 3R’s [70] recently included into most 
of the new international legislative bodies (see, for 
example, EU REACH Regulation, 2006 - at http: //ec. 
europa.eu/enterprise/sectors/chemicals/reach/index_en
.htm - and European Directive 2010/63 EU - available 
at http: //eur-lex.europa.eu/LexUriServ/LexUriServ.do? 
uri=OJ: L: 2010: 276: 0033: 0079: en: PDF), 
encourage/ compel the reduction / elimination in the 
use of animal models in basic and applied research 
studies. In order to overcome such limitations, new and 
relevant in vitro models need to be developed. 
Because of the complexity, variability and 
heterogeneity of tumors (intra-tumor’s physical, 
biochemical cues and molecular gradients -zonation of 
tumor- and differences between patients and tumor 
types), it clearly emerges that a battery of human-
derived in vitro/ex vivo models must be 
developed/optimized to better respond to clinical 
needs.  
In conclusion, it clearly appears that it is important 
(and urgent) to increase our knowledge of the tumor 
microenvironment, in order to better control and target 
it. This is the reason why in vitro models, able to 
reproduce all the fundamental cues and features of the 
tissue-specific native microenvironment, the complex 
network of cell-cell’s/cell-matrix’s, and cell-bioactive 
molecules’ interactions, need to be developed. In vitro 
models should, then, take into consideration (and 
resume) the complexity of the tumor microenvironment. 
To this aim, it should be better to consider a tumor as a 
complex organ, in which a wide variety of cells coexist, 
that secrete a high quantity of soluble factors (growth 
factors, cytokines, chemokines, proteolytic enzymes, 
etc.), that interfere with cells’ behavior but, also, with 
the physiological tissue remodeling process or with 
tensegrity; these last, in turn, control/may affect cells’ 
behavior and, consequently, ECM features. 
3.1. 2D versus 3D Cancer Models 
Cell culture systems were initially designed in order 
to simplify the complex in vivo context, and they allow a 
specific control on environmental conditions and have 
the advantage of being more reproducible and cheaper 
than in vivo models. The majority of in vitro models are 
characterized by the maintenance of cells in 2 
dimensions (2D) (artificial, rigid, plastic surface of 
traditional Petri dishes). Several mechanistic in vitro 
studies have been performed in such 2D culture 
systems, which are very distant from the physiologic in 
vivo conditions where cells develop and function; even 
if they represent a fundamental source of information 
into key biologic phenomena linked to neoplastic 
transformation (elucidation of specific signaling 
pathways’ perturbation, genetics of oncogenes and 
tumor suppressor genes, mechanisms of action of 
tumor promoters and mutagens, etc.), these systems 
are often too limited to correctly mimic the complexity 
and heterogeneity of the tumor/tumor’s microenviron-
ment interaction, and fail in simulating real cell behavior 
in living organisms. Whereas, in vivo, cells naturally 
grow in a three dimensional (3D) context that, besides 
allowing the correct polarization and orientation of cells, 
provide them with the surrounding matrix, that 
represents a dynamic environment that furnish cells 
with an architectural support, temporally-regulated 
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biochemical and biomechanical cues, and specific 
interactions with neighboring cells and matrix; whereas, 
in the classical 2D in vitro configuration, culture 
conditions impose an unnatural cell polarization, a loss 
of cell organization - with disrupted interactions 
between cells and cell/ECM, caused by the disruption 
of normal tissue architecture - and the loss of native 
ECM, with the consequence of affecting, in such a way, 
biomechanical cues and critical biological processes, 
such as cell proliferation, viability, migration, differen-
tiation, and specific cross-talks, as well [69, 71-74]. 
Moreover, the “flat” 2D conditions, lacking native ECM, 
does not mimic the natural tumor’s microenvironment 
that normally interfere with drug bioavailability, 
rendering, in such a way, a hardly effective 
extrapolation of drug activity from in vitro studies to 
clinical applications. As for normal tissues, culture 
models may be more or less complex, and reflect, 
more or less accurately, the in vivo specificities of the 
native tissue. Briefly, from the simpler to the more 
complex in vitro models, biological studies can be 
performed on isolated subcellular fractions, micro-
somes, single isolated cells, cells in suspensions, 2D 
cultured cells (homotypic or heterotypic cultures), and 
3D cultures (multilayered confluent cells, multicellular 
spheroids, with or without scaffolds, in mono- or hetero-
typic configurations, tissue slices, organotypic systems) 
[69, 75, 76]. Often, the more the system model is 
simplified, the less it is able to maintain, at long-term, 
cells’ viability and functions. As in the case of 
untransformed, normal cells, cancer cells also, when 
maintained in 3D culture, exhibit behavior and gene 
expression patterns closer to the in vivo conditions [77-
79]. Already in the ‘70s, Bissel’s group and others 
demonstrated how tissue architecture, 3D context, 
composition of ECM, correct cell polarization, and 
epithelial adhesion are fundamental for reproducing 
relevant in vitro models able to mirror, as much as 
possible, the physiological or pathological features of 
breast tissue [80, 81]. They showed that the 3D culture 
better recapitulates different tumors’ behavior than did 
2D configurations. For example, it was demonstrated 
that the 3D context was able to reverse tumor 
phenotype to normal (with specific pathways’ 
inhibitors), and to sustain the cross-talk between 
integrin and EGF receptors; moreover, tumor cells 
cultured in 3D showed, with respect to 2D-cultured 
controls, an increased pro-angiogenic capacity and a 
higher resistance to IFN, chemotherapeutic agents and 
irradiation [82, 83]. Other parameters that are highly 
modified by the switch from 2D to 3D configuration are 
the cell migration, cell morphology and cell signaling 
[84, 85]. Some other advantages of the 3D vs. 2D 
culturing techniques for investigating tumor’s behavior 
are also illustrated and discussed by Ferrarini et al. 
[86]. Moreover, some biological events that can be 
preferentially studied in 3D models are presented in 
Table 1. 
 
Table 1: Examples of in vitro Models Applied to the Study of the Main Cancer Hallmarks 
Biological events Models Outcomes References 
Cell invasion, 
migration, motility 
and metastasis 
• Matrigel
TM
 based assay 
• Type I collagen assay  
• Type I collagen overlaying 
3D assay 
• Multicellular spheroids 
• Acellular matrices  
• Co-cultures of bone 
sections with tumor cells in 
roller tube system. 
• Co-cultures of Non-Small-
Cell Lung Carcinoma Cells 
with bronchial mucosa 
• Microfluidic models  
• Nanoimprinted scaffolds 
 
 
• The outgrowth of cells from multicellular spheroids (consents to 
isolate the migration process from the complex multicellular 
context).  
• Hydrogel based assays allow investigation of factors and 
pathways involved in migration as well as dynamics regulating 
this process. 
• ECMs produced by fibroblasts at different stages of tumor 
progression allow to reproduce the matrix/tumor cells 
interactions and their involvement in 
tumorigenesis/invasiveness. 
• Co-culture systems seem efficient in reproducing 
? bone tropisms of tumor cells originating from breast or 
prostate. 
? bronchial mucosa invasion by lung carcinoma cells.  
• Microfluidic models allow interesting studies of metastatic 
process by culturing in 3D different cell types (tumor cells, cells 
of target organ etc). A limit of these models (for metastasis 
investigation) is that it is necessary to know in advance the 
main step of the different processes (intra-, extravasation, 
target organs). Concerning the easier tumor growth, cell 
migration approaches, they allow a good survival of 3D 
cocultures.  
• Micro- and nano-engineering represent the future of tissue 
engineering for conducting cell behavior, up today few of these 
models are applied to tumor biology. 
[242, 319-
329] 
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Table 1 Continue ….. 
Biological events Models Outcomes References 
Angiogenesis 
• Matrigel
TM
 or collagen 
based assays with cells or 
aortic explants.  
• 3D sprouting angiogenesis 
assay. 
• Organotypic co-culture 
assays 
• Outgrowth or migration of cells is evaluated after different 
period of time. 
• Co-culture assays, where fibroblasts can serve as ECM 
producer; the three dimensionality is mainly provided by the 
fibroblast layer. 
• After some days, sprouting/branchings or neo-capillaries (tube 
like structures) may be observed in response to biological 
stimuli (growth factors). 
• It is important to choose the good (anatomical) source of 
endothelial cells. 
• None of the actual in vitro model accurately reproduce the 
whole in vivo process of angiogenesis, mainly because of the 
complexity of the neovascularisaztion events that, for example, 
also includes the regulation of the neoangiogenesis by the fluid 
flows.  
[11, 99, 116, 
330-334] 
Drug 
responsiveness/ 
resistance / testing 
• Multicellular aggregates in 
static or dynamic conditions 
• Multilayered postconfluent 
culture 
• Hydrogel based cultures 
• Tissue slices 
• Cells express more differentiated functions and resemble more 
closely to in vivo situation. 
• Cell maintained in 3D often exhibit an increase resistance to 
chemotherapeutic drugs as compared to cells maintained in 2D 
configuration. According to the tumor cell type and the 
configuration of the 3D models, cells can gain or lose drug 
sensitization reproducing the native features of tumor. 
• Synthetic scaffold/hydrogels leading to better monitor ECM 
mechanics may allow to take into account the influence of the 
physicochemical properties of ECM onto drug bioavailability 
and diffusion. 
[71, 87, 116-
117, 335-339] 
Tumor growth 
• 3D free floating multicellular 
spheroids (mono and 
heterotypic), gel embedded 
spheroids, in static or 
dynamic culture conditions  
 
• Several tumor features (cell proliferation, intercellular contacts 
and interactions, cell-matrix interactions, hypoxia, HIF-1a 
expression and relative consequences) can be reproduced. 
• Coculture in dynamic conditions also consent to recreate, at 
least in part, the complex bone marrow microenvironment and 
are applicable in studying hematopoietic niche in health or 
illness.  
[90, 115, 120 
122, 337] 
Microenvironment 
influence 
• 3D culture in/onto natural 
and/or synthetic scaffolds 
• ECM mechanics (compliance, stiffness) can be better controlled 
by using synthetic scaffolds. 
[77, 78, 99, 
115-121] 
Tumor reversion 
• Culture of tumor cell in/on 
normal basal membrane or 
in low stiffness  
• ECM leads to the recovery of “normal” cell behavior (slower 
growth, epithelial like polarization ecc). 
[59, 340-341] 
 
3.2. 3D Tumor Models 
A first step in increasing the complexity of the 
microenvironment is the culture of multilayered post-
confluent cells. In these systems, cells are maintained 
on V-bottomed microplates and grow as multilayers (up 
to 15 layers can be assembled), harboring properties 
that look like those of native tumor, thus suggesting 
that these models could be suitable for drug screening 
[75]. The 3D culture of multilayered cells was further 
developed by Simon and collaborators [87], by using 
breast cancer-derived cells, but a deeper characteri-
zation of cell model’s properties is required in order to 
ascertain the capability of correctly reproducing the 
tumor environment.  
The 3D culture models of tumor cells that are at 
present most extensively used are represented by the 
culture of multicellular spheroids (MSs), that consists in 
the self-aggregation of (neoplastic) cells in multicellular, 
rounded aggregates (spheroids). These spheroids can 
be obtained by different methods (e.g. coated-plates, 
hanging drops, liquid-overlay techniques, hydrogel 
templates, micro-patterned wells). Spheroids can also 
spontaneously form in dynamic bioreactors (such as 
spinner flasks or Rotary Cell Culture System’s - 
RCCS
TM
 - devices), or by microfluidics-based 
technologies, with or without scaffolds [88-90]. 
Spheroids show a particular cellular microenvironment, 
since they are able to reproduce, at least in part, key 
3D tissue-like features known to influence cell behavior 
and gene expression (i.e. organization, zonation, ECM 
deposition, cell-cell and cell-matrix interactions). Due to 
a low mass transfer condition, these peculiar tissue-like 
3D constructs display various similarities depending on 
tumor mass, and, in particular, gradients of nutrients, 
metabolites, catabolites’s wastes and growth factors, 
associated with low O2, and high CO2 concentrations 
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[91]. If spheroids grow up to 500 μm diameter, a central 
necrotic core appears, reproducing in such a way the 
hypoxic and necrotic processes usually observed in 
solid tumors [92, 93]. Cells grown in MSs usually 
exhibit a lower sensitivity to therapeutic drugs and a 
more specific response to particular therapeutic agents 
as a result of new signaling pathways activation [94, 
95]. In living organisms, in addition to the involvement 
of particular proteins (such as the drug/ABC 
transporters, enzymes and HMGB1), or to the 
increased efficiency in DNA repairing mechanisms and 
resistance to apoptosis, multi-drug resistance may also 
be due to ECM’s organization and composition 
(desmoplasia), cell-cell adhesion and lower growth 
rate, which are parameters that mirror the in vivo 
context, in which tissue architecture and cell adhesion, 
as well as the absence of blood vessel and the low 
hydrostatic and osmotic pressure, limit the diffusion of 
therapeutic drugs [83, 96, 97] . 
In addition, when cells grow in spheroids, they form 
an outer layer of proliferative cells and a more central 
quiescent zone where cells do not proliferate. Since 
chemotherapeutic drugs often target the dividing cells, 
this quiescence may justify the “resistance” to cyto-
static drugs observed in MSs [89, 98]. Furthermore, in 
vivo, drug bioavailability and delivery are also regulated 
by the ECM’s attributes (configuration, composition, 
structure), that can alter/disrupt cell signaling [99, 100]. 
Heterotypic MSs more closely mimic the heterogeneity 
of tumors and the heterotypic inter-relations between 
cells, and, in addition to monotypic culture, they allow 
the investigation of important tumor endpoints such as 
angiogenesis, tumor cell migration and invasion, and 
drug responsiveness [101]. Examples of heterotypic 
spheroids may encompass tumor cells with fibroblasts, 
macrophages, and endothelial cells [102, 103]. For 
example, heterotypic MSs of melanoma cell lines and 
endothelial cells allowed to demonstrate that invasion 
and angiogenesis processes may be potentiated by 
cadherins [104]. Co-cultures of fibroblasts and 
cheratinocytes can be also used to form 3D models of 
reconstructed skin, in which melanoma or other skin 
cancer cells can be embedded. Within these 3D skin 
reconstructed models, melanoma’s cells from different 
stages of tumor progression have the same properties 
they show in the patients’ skin. For instance, melanoma 
cells at the initial radial growth phase are unable to 
invade the dermis from the epidermis, whereas, in 
advanced stages such as the vertical growth phase 
and the metastatic phase, cells readily invade the 
dermis [105]. A number of recent studies have 
assessed the effects of novel anti-cancer drugs in 3D 
models of reconstructed skin [105, 106]. Alternatively, 
multicellular aggregates can be formed by a unique cell 
type for generating tissue-like structures and, then, 
they can be further co-cultured with tumor’ cells, in 
order to observe the reciprocal interaction of both cell 
types [107]. Important limits of these MS-based models 
are: i) some cells are not able to aggregate in order to 
form multicellular spheroids; ii) the spatial arrangement 
of cells could be casual and could not match the in vivo 
co-localization of specific cells; iii) cell ratio inside 
multicellular spheroids does not always reflect the real 
proportion of cells in the tumor’s environment; iv) co-
cultures should involve different tumor cells (in addition 
to non-tumor cells), in order to better mimic tumor’s 
heterogeneity; v) 3D MS’s culture require very efficient 
dynamic bioreactors, which can allow a long-term 
culture of the spheroids, so that the maturation of the 
neo-synthesized ECM may take place and achieve 
characteristics close to the situation in vivo, vi) cell 
amplification and aggregation can be time consuming 
experimental procedures, vii) while heterotypic cultures 
can mimic the reciprocal cross-talk of tumor’s with 
neighboring cells (thus mirroring the in vivo tumor 
context better than in other in vitro model systems), 
these co-culture conditions make it more difficult to 
distinguish among all cell types, which of them is 
responsible of the biological effects observed in 
response to external stimuli. 
3.3. Mimicking the ECM 
One of the most important challenges for finding the 
3D culture model more suitable for each specific 
experimental purpose, is to also engineer ECM, so that 
neo-constituted matrices are obtained with structural 
and biochemical features similar to those of the specific 
native matrix of the tissue under study. This means that 
it is important to reproduce both the mechanical 
(architectural, topographic, physical features and tissue 
mechanics: ECM dimensionality, collagen fiber size 
and orientation, ECM stiffness/compliance), and the 
biochemically- and biologically-active ECM’s 
characteristics (ligand-binding sites) [108, 109]. 
One of the most used “biological” ECM is that 
extracted from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma’s cells (most diffused trade names: Matrigel
TM
, 
Cultrex BME
TM
). This tumor-derived matrix has the 
characteristics of a basement membrane-like matrix, 
since it is mainly composed of type IV collagen, 
laminin, perlecan, nidogen/entactin and trophic factors 
[110, 111]. It was shown to sustain 3D cultures of 
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breast-, colon-, prostate-, and lung-derived tumor cells, 
allow expression of some of their original tissue-
specific functions and to allow co-culturing, thus 
confirming, for example, that, in an in vitro prostate 
tumor model, stromal cells might activate tumor growth 
and invasion’s process [74, 79, 112-114]. However, this 
extractive matrix, besides being variable in quality from 
batch to batch, fails, at least in part, in recreating the 
native mechanics of normal basement membrane, and 
does not correspond at all to the other matrices found 
within connective tissues and parenchyma. This 
mouse-derived matrix does not represent the ECM of 
all tumors, since, as reported before, each tumor 
possesses its own characteristics, which also vary in 
accordance with its evolution. Therefore, it is of interest 
to be able to isolate/customize/bioengineer the tissue-
/tumor- specific 3D matrices. Several strategies were 
developed to respond to this need, and a number of 
natural (hyaluronan, chitosan, collagen, alginate, fibrin, 
laminin-rich ECM proteins) or synthetic matrix/gel/ 
hydrogels/scaffolds were proposed (e.g. Poly(lactide-
coglycolide), poly(lactic acid), poly(vinyl alcohol), 
poly(?-caprolactone) or polyethylene glycol) (e.g. 
Poly(lactide-coglycolide), poly(lactic acid), poly(vinyl 
alcohol), poly(?-caprolactone) or polyethylene glycol) 
[77, 78, 99, 115-121]. One advantage of scaffold-based 
strategies is that it is possible to better manage matrix 
stiffness/compliance, porosity, and biochemical 
composition. 
Among the various available ECM substitutes, 
collagen gels seem to represent an interesting option, 
especially if cross-linked with other matrix components 
[120]. Unfortunately, as in the case of Matrigel
TM,
 
analogous, collagen hydrogels also have a noteworthy 
difference between the different preparations. In 
collagen gels, monotypic or heterotypic cultures can be 
developed, thereby increasing the possibility of better 
mirroring the in vivo conditions by integrating tumor’s 
neighboring cell types [122]. Culture of fibroblasts in 
collagen gels have allowed a better understanding of 
the reciprocal interactions between cells and ECM, 
and, namely, the regulation of cell behavior mediated 
by the mechanical properties of ECM [123].
 
Type I collagen can be electrospun and, therefore, it 
can support cell growth. By acting on ECM 
biomechanics, it also provides oriented fiber alignment-
signals - or topological cues - known to regulate cell 
behavior. Hydrogels with a mixture of Matrigel
TM
 and 
type I collagen were shown to present stiffness 
properties ranging from normal to breast tumor tissue 
[59], and to sustain multicellular cultures and tissue-like 
morphogenesis [124]. Scaffolds formed of chitosan and 
alginate’s mixture were shown to better favor the tumor 
progression of human-derived glioma cells than does 
each component alone [125]. Moreover, scaffolds/ 
hydrogels can be functionalized to favor more native 
cell behavior and more tissue-like function [99] . Hence, 
the choice of natural matrix-derivatives and 
configurations is also of importance, since, as in in vivo 
tumors, it undoubtedly influences cell behavior, from 
cancer reversion to promotion steps.  
Alternatively, some in vitro models have been 
developed, by using decellularized matrices and, even 
if their use for cancer investigations is still limited, they 
could represent an important source of natural ECM. 
The major advantages of these decellularized matrices 
are that they can be prepared from different tissues, 
maintaining the 3D architecture of the native tissue and 
its original composition. These matrices were used for 
investigating the behavior of breast tumor-derived cells 
(proliferation, morphology, migration) and their drug 
sensitivity, that were shown to be quite similar to what 
can be obtained with the in vivo xenograft models 
[126]. In particular ECM, prepared by using different 
explants obtained from human intestinal mucosae 
(ranging from healthy colon to colorectal carcinoma), 
can also be used to investigate tumor cell’s behavior in 
response to a more or less permissive microenviron-
ment [127]. The main limit of this ECM is that they are 
natively complex, their exact composition is not fully 
known, and this may render difficult the interpretation of 
cell’s behavior in response to a particular stimulus. 
 Synthetic matrices could also be regarded as the 
future of engineering tumor microenvironments, but the 
high number of biomaterials proposed in the literature 
need to be further optimized before being effectively 
applied in the tumor biology fields [128]. In effect, in the 
design of these matrices, several key factors should be 
taken into account, and, among them, landscape/ 
topography, fiber orientation, porosity (macro-, micro-, 
nanoscale conditioning), matrix viscoelasticity, matrix 
remodeling, and growth factors’ and cytokines’ binding 
sites. It is now easier than before to monitor / engineer 
matrix compositions (collagen, proteoglycans, other 
macromolecules), to include adhesion peptides (the 
integrin-binding Arg-Gly-Asp motif RGD, for example), 
to functionalize the surface of the scaffolds/hydrogels, 
to control biomaterials’ mechanical properties [129], to 
model cell behavior in space and time, and to develop 
patterning strategies providing a biomaterial substrate 
conducive to support a particular geometric configura-
tion. 
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3.4. Which Cells for 3D Cultures? 
Another important point that it is necessary to keep 
in mind is the choice of the cells to be used in the 3D in 
vitro models. There is a high number of available cell 
lines that express some specific tumor features, and a 
number of them have already been well characterized 
[130]. Nevertheless, the native heterogeneity of tumors 
renders difficult the choice of one suitable cell line, 
since cell lines could represent only one clone among 
the whole mosaics of tumor cells. Moreover, the use of 
freshly isolated cells from patients’ tumors allows to 
work on primary cells, by avoiding the phenotypic drift 
related to the culture conditions. However, the risk 
exists that the experimental procedures employed for 
cell isolation and culture may exert a selective 
pressure, giving rise to clones able to survive and to 
eliminate more labile cells, with the consequent loss of 
the native cell heterogeneity typical of neoplastic 
tissue. 
Interesting approaches based on the use of the 
native tissues were developed for different tumor-
derived tissues, overcoming, in such a way, the 
limitation related to cell isolation. These models are 
mainly represented by the culture of tissue slices or 
explants. Both these approaches allow the 
maintenance of the 3D tissue architecture, cell 
organization, matrix arrangement and composition, i.e. 
the complexity and heterogeneity of the tissue 
microenvironment. Moreover, both models allow 
working with human tissues (healthy- or tumor-derived 
tissues), solving the problem of interspecies differences 
that occur when animal models are used. This allows a 
more accurate prediction of the human in vivo cell 
behavior. Tissue slices were applied to cancer 
research in order to analyze therapeutic strategies and 
drug responses, as well as to gain new insight into the 
cell invasion process [131-133]. 
The more complex culture of tissue explants is 
appealing, since it offers the possibility of maintaining a 
more consistent section of tissue (thickness of more 
than 1 mm vs. 250 μm, for explants and tissue slices, 
respectively), thus increasing the possibility of preserv-
ing multilayer cell-cell and cell-matrix interactions [134]. 
Once correctly established and optimised, the model 
based on the use of tissue explants can allow long-
term experimental procedures, thus representing a 
potent tool for preclinical investigation of therapeutic 
drugs targeted on individual patients. Today, the limit of 
these tissue slices- and explants-based models is the  
 
difficulty of optimizing the protocols of ex vivo culture, 
since 3D hydrodynamic conditions and high mass 
transfer are essential to sustain cell viability and native 
tissue functions.  
Even if 3D cultures lack some aspects of the whole 
in vivo environment (e.g. systemic interrelations, 
immune response, hormonal inputs), they differ from 
2D conditions, that offer more cell signaling information 
and less tissue-like features. With respect to 2D 
cultures, 3D models also better resemble animal in vivo 
models, bridging the gap between these two models, 
routinely used in cancer research. However, 3D in vitro 
/ex vivo models still need to be optimized in order to 
overcome a number of limitations (Table 2). Among 
these limits, time consuming procedures and lack of 
reproducibility are the most urgent to solve, especially if 
these models will be used for drug screening purposes 
in pharmaco-toxicology field. 
4. LEUKEMIA 
Leukemia is the most common neoplasms in 
children and accounts for almost a third (30%) of the 
tumors at diagnosis. Pediatric leukemias occur 
predominantly as acute leukemias, with acute 
lymphatic leukemias (ALL) representing the largest 
proportion (about 80% of all childhood leukemias) 
followed by the acute myeloid leukemias (AML, 
accounting for about 10% of all childhood leukemias) 
[12, 135]. Leukemic cells inhibit hematopoiesis and 
infiltrate organs, eliciting the main clinical manifesta-
tions, such as anemia, bleeding and infections. 
Leukemic infiltration of lymph nodes, the spleen and 
the liver may alter their function and increase their size. 
Moreover, testes and CNS are often infiltrated by 
leukemia cells [136]. 
4.1. Normal and Leukemic BM Microenvironment  
Several lines of evidence suggest that the bone 
marrow (BM) microenvironment plays a central role in 
the control of leukemia initiation, progression, and 
drug-resistance. The BM microenvironment consists a 
complex 3D highly vascularized architecture of multiple 
cellular components, soluble factors, all embedded in 
an ECM. The cellular component of BM can be divided 
into hematopoietic cells and the BM stromal cells 
(BMSCs). The hematopoietic stem cells (HSCs) are 
localized within the BM in two main niches: the 
osteoblastic niche (at the bone-BM interface) and the 
vascular niche (around the blood vessels). This  
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localization is required to maintain their self-renewal 
capacity [137, 138]. BMSCs include several cell types, 
such as endothelial cells, perivascular reticular cells, 
osteoclasts, osteoblasts, mesenchymal stem or stromal 
cells (MSCs), all of them important for HSC 
maintenance. Moreover, other stromal cells (glial cells, 
neuronal cells, adipocytes) can regulate hematopoiesis 
[139]. 
MSCs play an important role in BM, since they give 
rise to several cell types, including endothelial cells, 
neurons, astrocytes, myocytes, chondroblasts, osteo-
blast and adipocytes [140, 141]. This heterogeneous 
population is responsible for the production and 
deposition of ECM, formed mainly by type I and IV 
collagens, proteoglycans, glycosaminoglycans such as 
HA, and glycoproteins such as fibronectin, osteopontin, 
laminins and thrombospondins [142]. http: //www.ncbi. 
nlm.nih.gov/pmc/articles/PMC3566109/-pone.0054778- 
Hines1. Moreover, ECM not only provides the structural 
scaffold for cellular element of BM, but also represents  
 
a reservoir of cytokines, chemokines, and growth 
factors, produced by hematopoietic cells and BMSCs. 
The interaction between tumor and stroma occurs 
through the expression of receptors on the surface of 
leukemic cells binding the stromal cells or through 
adhesive ligands present both on stromal cell or ECM. 
Collectively, the BM architecture allows myelopoiesis, 
lymphopoiesis and immunoregulation processes in 
close physical proximity [143]. Accumulating evidence 
suggests that BM niches promote proliferation of a 
subpopulation of leukemic stem cells (LSCs), enhance 
their survival, and protect them from chemotherapy. 
Thus, the BM microenvironment has been proposed as 
a sanctuary for minimal residual disease, responsible 
for the occurrence of relapses, in several leukemias, 
including AML and ALL [144-146]. These events are 
mediated by the interaction between leukemic tumor 
cells/LSCs with specific components of ECM, with 
soluble factors present in the BM microenvironment or 
BMSCs. The processes of homing, mediated by 
soluble factors such as SDF-1, and the adhesion to the  
 
Table 2: Main Shortcomings of 3D Culture Models and Proposals to Overcome them 
Shortcomings of 3D culture models 
Weakness Counteractions to circumvent limitations 
Models are often limited to short 
term studies  
• Develop effective bioreactors 
Whole tumor complexity is lost 
• Increase multicellular cultures approaches 
• Increase microengineering approaches (microfluidics, microfabrications, micropatterning) 
• Recover the native tissue mechanical cues 
• These necessary developments, are difficult to reach because of the high variability between 
tumor types, and inside tumor itself; a promising strategy may be to develop patient-biopsies  
cultures, but they will be hard to handle in the high throughput context and they are poorly 
available 
Differences/variability between 
3D models in pre-clinical assays 
• Standardization of procedures and methods  
• Standardization for preparation of good/constant quality scaffold/hydrogels 
• The high number of available models and their relative strength and weakness force an aware 
choice of the model for defined application (because of tumor heterogeneity and the actual lack of 
perfect in vitro model, it is necessary to keep in mind that each in vitro system could model only 
partly the conditions in living organisms)  
Application of Tissue engineering 
to tumor biology 
• Microfluidic approaches offers good prospective applications, but need further investigation to 
render them easy to use, less expensive when thinking to high-throughput applications 
Lack of suitable methods for 
drug screening in high 
throughput contexts 
• Both cell models and analytic protocols should be optimized and standardized.  
• Models should consent to cover as much as possible the whole tumor /tumor microenvironment 
characteristics (these models are still lacking) 
• Scaffold/hydrogel/ medium etc (all components of the in vitro models should be tested for its 
interactions with drugs to eliminate experimental bias) 
Loss of systemic regulations 
• This gap could be bridge with the development of multi-compartmental bioreactors or bioreactor 
organized as parallel or series networks (but use of animals will remain necessary even if reduced) 
Cost-effectiveness 
• Standardization of procedures 
• Optimization of techniques for biological investigations 
• Research of more suitable models to reach equilibrium between reliability and cost 
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stromal niche, thanks to adhesion molecules like CD44 
or VLA4 integrins, are crucial events. The sequestered 
leukemic cells can proliferate thanks to several growth 
factors, cytokines, pro-angiogenic factors present in the 
BM stroma [145]. Interestingly, the adhesion of 
leukemic cells to the stromal niche elicit a better 
survival rate. Several mechanisms have been 
proposed to explain this feature, such as the induction 
of the cell adhesion-mediated drug resistance 
phenomenon (CAM-DR) [147, 148], the induction of a 
reversible quiescent state, that favors cell survival 
because most standard chemotherapies act on 
proliferating cells [145] and the increase of hypoxic 
areas which contributes to chemoresistance of 
leukemic cells http: //www.ncbi.nlm.nih.gov/pmc/ 
articles/PMC3414410/ - R10 [149]. The discovery of 
this complex network, in which the leukemic cells are 
only one of the participating players, suggests that 
more effective molecular therapies should target not 
only leukemic cells but also their microenvironment 
[150, 151]. Thus, useful leukemia models should 
reproduce not only a generic 3D environment, but also 
the specific leukemia microenvironment, represented 
by BMSCs, specific components of ECM or soluble 
factors embedded.  
4.2. 3D Leukemia Models 
Relatively few 3D models have been specifically set 
up for AML and ALL, thus multiple myeloma (MM) and 
chronic myelogenous myeloid leukemia (CML) and 3D 
models have also been considered in this review.  
4.2.1. Leukemia Cell Lines on Scaffolds 
The widely used 3D model of cellular spheroids, 
formed by spontaneous aggregation of cells, is well 
suitable for adherent cells but not for leukemia cells, 
that grow in suspension. Thus, leukemia cells 
necessarily need a support, such as a scaffold, 
eventually coated with an ECM component. Blanco and 
collaborators [152] evaluated the adhesion and the 
proliferation of several AML cell lines on different 
polymeric scaffolds, coated with ECM proteins. They 
showed that the polyurethane (PU) scaffold coated with 
collagen type I had the best performance, allowing the 
cell growth for over 6 weeks in the absence of 
exogenous growth factors.Vu and collaborators [153] 
produced an alginate hydrogel able to mimic 3D soft 
marrow tissue. The addition of the RGD peptide, the 
integrin-binding motif, to the hydrogel promoted further 
K562 leukemic cell growth and enhanced cell 
differentiation. 
4.2.2. Co-Culturing Leukemia Cell Lines and BM 
Stroma Cells  
Increasing complexity can be achieved by co-
culturing a leukemia cell line with BM stroma cells. 
Dainiak and collaborators [154] used, as a scaffold, a 
polyacrylamide-based macroporous hydrogel (MH), 
functionalized with the type I collagen and with a 
structural analogue of the cell adhesive peptide RGD. 
MHs scaffolds with differently functionalized surfaces 
have been seeded with the human acute myeloid KG-1 
leukemia cell line cultured with human embryonic 
fibroblast on MHs. The authors found out that leukemia 
cancer cells formed multicellular aggregates on 
collagen or RGD-like functionalized MHs but not on 
plain MHs and that KG-1 aggregates were more 
resistant to the treatment with the chemotherapeutic 
drug Arabinofuranosyl Cytidine (Ara-C).  
The increased resistance to chemotherapeutic 
agents in a 3D environment, with respect to the 
corresponding 2D model, is a common feature not only 
in leukemia cell but also in other tumor types [78]. 
Moreover, the co-culture system results in a further 
increase of the chemoresistance. Indeed, Alitawi and 
collaborators [155] developed and characterized an in 
vitro 3D co-culture system where leukemia cell lines 
were seeded with human BM MSCs on a polyglycolic 
acid/poly-l-lactic acid (PGA/PLLA) copolymer scaffold. 
The effects of cytotoxic agents, such as doxorubicin or 
cytarabine, were evaluated and results were compared 
to those obtained by culturing leukemic cells alone in 
suspension (2D monoculture), or growing over a 
monolayer of expanded hu-BM-MSCs (2D co-culture). 
The authors demonstrated that 2D and 3D co-culture 
conditions showed less cytotoxicity of chemotherapy 
when compared to the 2D monoculture condition and 
that the 3D co-cultures achieved the highest resistance 
to chemotherapy. Moreover, these authors tested the 
capacity of free diffusion of molecules with different 
weights inside the PGA/PLLA scaffold, showing that it 
allows free diffusion of molecules up to 1000 Da [155]. 
This is one of the major issues in designing a 3D model 
for chemotherapy, since the 3D model need to allow 
media components and cytotoxic agents to diffuse 
freely to target cells.  
An innovative 3D model was set up by Usuludin and 
coworkers [156]. They developed a hematopoietic co-
culture system using the hollow fiber bioreactor (HFBR, 
purchase from FiberCell Systems Inc., Federick, MD, 
USA). An immortalized human BM stromal cell line, 
HS-5, was first established and maintained for up to 28 
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days in the HFBR. Subsequently, K562 erythro-
leukemia cells were added to the bioreactor. The HFBR 
co-cultures enhanced proliferation of leukemic cells, 
compared to a standard 2D condition. Moreover, in 2D 
cultures, cells differentiated along the erythrocyte and 
monocyte pathways, but retained a subpopulation of 
myeloid progenitors. On the contrary, HFBR co-
cultures showed multilineage differentiation pathways, 
such as the megakaryocytic, and the monocytic 
lineages, while erythroid differentiation was inhibited. 
Importantly, the cells expanded in the HFBR culture 
were mostly adherents, emphasizing the importance of 
cell-cell contact for leukemic cell proliferation.  
4.2.3. 3D Leukemia Models with Primary Cultures 
A very interesting application for leukemia 3D 
models is the ex vivo expansion of the leukemic cells 
isolated by patients. It has been demonstrated that 
primary leukemia cultures better survive and proliferate 
in a 3D mimicry with respect to classical 2D techniques 
[157, 158]. One of the most important advantages 
consists of having a sufficient number of neoplastic 
cells to identify the most effective drugs. Patient 
specimens that are derived from BM biopsies or 
peripheral blood often contain too few neoplastic cells 
in order to test drug effectiveness. Accordingly, 3D ex 
vivo expansion of primary tumor cells would allow the 
identification of personalized drugs. 
Kirchner and collaborators [157] reconstructed a 3D 
BM ambient, by coating BMCs in fibronectin/Matrigel
TM
 
mixture on a collagen I/fibronectin scaffold. In this 3D 
issue culture model, they succeeded in expanding 
multiple myeloma (MM) clones isolated by BM 
mononuclear cells (BMCs) of aspirates, so that it was 
possible to test the anti-tumoral efficacy of well-known 
drugs, such as Melphalan and Bortezomib. Intriguingly, 
Hou and coworkers [158] have succeeded in 
reproducing a ‘biomimetic osteoblast niche’ with bio-
derived bone as a scaffold, coated with osteoblasts 
obtained by differentiating MSCs of CML patients. The 
reconstructed osteoblast niche maintained stem/ 
progenitor cells from BM of patients CML for a long 
period of culture, more efficiently than the 2D culture 
system.  
4.2.4. Ex vivo Maintenance of BM Biopsies in 
Bioreactors 
Up to date, Ferrarini and collaborators set up the 
first 3D dynamic culture system for BM biopsies 
derived from patients with hematological tumors. The 
authors used the Rotary Cell Culture System (RCCS
TM
) 
Bioreactor, a device specifically designed to culture 
cells in a 3D milieu in microgravity. The RCCS
TM
 was 
applied to ex vivo cultures of MM specimens [134], 
obtaining long-term cultures of myeloma tissue 
explants. Stained histological slices showed a 
preserved architecture in which viable MM cells were 
embedded in their native microenvironment, compre-
hensive of the lamellar bone and vessels. The ex vivo 
cultures of MM specimens in the RCCS
TM
 bioreactor 
were also used to test the antitumoral efficacy of the 
proteasome inhibitor Bortezomib, a well-known drug 
used in MM therapy. Remarkably, the beta2-
microglobulin levels, a proliferative marker commonly 
used for staging of MM, in patients' sera before and 
after the drug therapy paralleled those observed in 
supernatants from the ex vivo cultures in presence/ 
absence of Bortezomib. Thus, these results showed an 
interesting concordance between the effects exerted by 
Bortezomib in vivo and ex vivo. Collectively, the results 
obtained on ex vivo cultures, showed that it was 
possible to maintain the original tissue architecture and 
the specific microenvironment for each patient, 
potentially allowing the maximum degree of 
predictability in drug response. 
4.2.5. 3D Microfluidic Tissue Models 
At the intersection of tissue engineering and 
microfluidics recent advances show that it is possible to 
grow in vitro 3D tissues by reproducing the nutrient and 
waste transport function of the microcirculation and the 
emulation of the shear stress effects. One of the most 
important advantages is also the use of very small 
amounts of reagents and cells and the real-time 
monitoring of cellular parameters. Several microfluidic 
devices have also been set up to emulate tumor growth 
in the BM microenvironment.  
Zhang and collaborators [159] have seeded the 
microfluidic culture chambers with a human osteo-
blastic cell line. This cell line easily adhered to the 
support and produced a measurable extracellular 
matrix (ECM), thus mimicking a tumor osteoblastic 
niche, which then facilitated the seeding of 
mononuclear cells from BM biopsy of MM patients. 
Real-time monitoring microscopy and flow cytometry 
post-analysis showed that this in vitro MM tissue model 
permitted the preservation and proliferation of primary 
human MM cells. Moreover, it recapitulated the 
essential interactions between malignant cells and the 
recreated endosteal niche, all within a perfused micro-
environment intended to mimic the fluidic features of 
the BM. The relevant clinical advantage, proposed by 
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the authors, is the requiring of very small amounts of 
patient-derived BM cells (< 1.10
6
 cells, for an eight-
chamber microfluidic device), allowing an accelerated 
evaluation of new therapeutics for the personalized 
treatment of multiple myeloma. 
Opposite to this dynamic microfluidic system, Khin 
and collaborators [160] have very recently set up a 
static 3D microfluidic device, allowing a co-culture of 
MM cell lines with the adherent BM-derived stromal cell 
line HS-5 or a co-culture of MM primary cells with 
patient mesenchymal cells. Static microfluidic devices 
do not allow the mimicking of the fluidic flow, however 
they avoid the possible generation of several artifacts, 
caused by the continuous flow (e.g. removal of soluble 
signals important for cell-cell communication, unvaried 
concentration of media components) typical of dynamic 
systems [161]. MM and stromal cells were mixed into 
the collagen/media mix and seeded in commercially 
available 3D cell-culture slides (m-slide Chemotaxis 3D 
Ibitreat from Ibidi, LLC). 3D co-cultured cells were 
exposed to Melphalan and Bortezomib, in order to set 
up a preclinical assay for chemosensitivity. Digital 
images obtained with live microscopy were analyzed to 
detect cell death after drug exposure. Using this 
platform, the authors were able to predict the 
chemosensitivity to Melphalan and Bortezomib in 
several MM patients [160]. 
4.2.6. 3D Leukemia Models for Testing Motility/ 
Invasion 
Infiltration of leukemia cells in several organs is a 
common feature of the disease. Specific assays for 
testing motility and invasion in the 3D milieu can be of 
interest. In cancer research, the most popular cellular 
invasion assay is the Transwell (or Boyden) chamber 
assay. Cancer cells are seeded on top of a thin gel 
containing ECM molecules, in turn positioned above a 
filter. The invasion capability is evaluated by counting 
the number of cells able to pass to the other side of the 
filter [162]. This assay is very appealing because of its 
speed and the ease in the quantitative analysis. 
However, the biological process is conducted in a 
limiting 2D milieu and only the end point is monitored. 
To overcome these problems the 2D well-known 
transwell assay has been adapted in order to study 
migration in 3D matrix. In 3D motility assay, cells are 
embedded within a thick matrix of seeded on top 
(collagen or Matrigel
TM
). Results are obtained by 
counting the number of migrating cells in the ECM gel 
[163]. Several authors have used the transwell  
 
chamber assay in 3D matrix for testing invasion ability 
of leukemia cells [164, 165]. This method was later 
refined, by observing leukemia cell motility in 3D 
Transwell with time-lapse microscopy. The image 
analysis allowed not only quantifying cell motility in the 
samples, but also to describe the type of motility, i.e. 
amoeboid or rolling type [166]. 
A similar and simplified method with respect to the 
3D Transwell assay consists of applying collagen or 
Matrigel
TM
, containing specific chemoattractants to be 
studied, directly into the cell culture plate and adding 
cell leukemia suspension on top. Cellular invasion was 
scored by evaluating the number of cells at different 
positions in the 3D matrices, by using an inverted 
microscope and a digital depth meter [167, 168]. A 
more complex 3D model for testing cell motility was 
developed by de Silva and collaborators [169], where 
they have fabricated an Inverted Colloidal Crystals 
(ICC) scaffold, with a 3D honeycomb-like structure from 
colloidal crystal templates. The internal dimensions of 
hydrogel-made pores, as well as the gel stiffness, were 
tuneable, thus rendering these ICC scaffolds suitable 
for cell invasion studies. The authors tested the 
migration ability of the acute promyelocytic leukemia 
NB4 cell line, which can differentiate with all-trans 
retinoic acid (ATRA) into mature, highly mobile 
neutrophils [170]. Fluorescent marked NB4 cells were 
seeded on the ICC scaffolds and the invasiveness was 
calculated by analyzing confocal images at different 
depths. The authors succeeded in clearly demonstra-
ting the ability of differentiated NB4 to enter the 
scaffold, while non-differentiated cells were only very 
occasionally found below the scaffold surface [169].  
4.2.7. 3D Models for Expanding Normal HSC, a Tool 
for Clinical Therapy 
Several 3D models have been developed in order to 
mimic normal BM niches [171-173]. Artificial analogues 
of BM can accelerate the understanding of 
hematopoiesis in humans or can be suitable for ex vivo 
simulation of some aspects of human immune 
response. Moreover, in the oncological field, these 3D 
models can be useful for in vitro production of human 
hematopoietic cells. Indeed, the HSCs transplantation, 
a widely used therapy for several hematological 
malignancies, presents two important limitations: an 
insufficient number of matching donors and the 
difficulty of obtaining enough cells [174]. Thus, 
expanding HSCs, obtained from donors, can be a 
suitable strategy to overcome these obstacles. 
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5. LYMPHOMA 
Lymphomas represent the third most common 
childhood malignancies. In under 15-year-olds they 
occur at a median age of 10 years and 8 months; non-
Hodgkin lymphoma-NHL (including Burkitt lymphoma) 
(6.6%) and Hodgkin lymphoma-HL (4.8%) are the most 
frequent diagnoses in this age group. The same pattern 
is seen in adolescents and young adults. Lymphomas, 
especially HL, are practically non-existent among 
young children [12]. More than 90% of pediatric NHLs 
are high grade lymphomas divided into four major 
histologic subtypes: diffuse large B-cell lymphoma, 
Burkitt lymphoma, lymphoblastic lymphoma and 
anaplastic large cell lymphoma.  
The two most common HL in children are the 
nodular sclerosis HL and the mixed cellularity HL. 
Lymphomas start generally in lymph nodes and diffuse 
through the lymphatic vessels to other lymph nodes or 
to the spleen, or to extranodal area, such as bone, BM, 
liver and lungs. Other lymphomas, in particular NHL, 
arise outside the lymph system, especially in the 
digestive tract (stomach, intestines, liver), thyroid gland 
or skin. 
5.1. Lymphoma Microenvironments  
With respect to solid tumor, dealing with lymphoma 
cancers is more complicate, since they can proliferate 
both in suspension and in several tissues [175]. As 
demonstrated in other tumors, the progression of 
lymphomas involves a complex interactions between 
neoplastic cells and their microenvironment, including 
the tumor's vascular system and the stromal cells. Due 
to the complexity of lymphoma malignancies, residing 
in different tissues, the microenvironment is charac-
terized by different populations. In BM, lymphoma cells 
are interacting with the BMSCs, already discussed in 
the leukemia paragraph. In secondary lymphoid 
organs, these non-malignant stromal cells consist of a 
heterogeneous group of cells, such as macrophages, 
follicular dendritic cells, follicular reticular cells, 
fibroblasts, B small lymphocytes, plasma cells, Th1 and 
Th2 cells, T regulatory cells (T-regs), eosinophils, mast 
cells and granulocytes. They are recruited and/or 
induced to proliferate by tumor cells and produce 
soluble or membrane-bound molecules involved in 
tumor cell growth and survival. The tumor-host 
communication is a complex network, involving 
adhesion molecules, chemokines, and chemokine 
receptors. The resulting tumor growth depends on the 
balance between the inhibitory and growth-promoting 
signals [176, 177]. Thus, in each tissue, lymphoma 
cells presents an unique network of signals, and 
therefore is hard to get targeted therapies [175, 178]. 
5.2. 3D Lymphoma Models 
The literature on 3D lymphoma models is very poor. 
This gap can be partially filled by considering that most 
of the 3D leukemia models are also suitable for 
lymphomas. However, to the best of our knowledge, 
the 3D reconstruction of the lymphoma microenviron-
ment, at least in lymph nodes, is completely missing. 
Much work remains to be done in this area. 
5.2.1. Scaffold-Free Lymphoma 3D Models  
As leukemic cells, lymphoma cells can not form 
cellular spheroids, typical of adherent cells. However, a 
method was recently proposed of forming 3D 
multicellular aggregates (MALC) of lymphoma cells 
[179] in vitro, by modifying the well-known hanging 
drop technique [180]. The t(14,18)+ follicular lymphoma 
RL cell line was used for this purpose and the growing 
cells formed compact oval-shaped aggregates, with ~1 
mm diameter, a dimension never reached with the 
standard 2D culture [179]. The gene expression 
profiles either from RL 2D cell suspension or from RL 
cells grown as MALC were analysed. Cells from MALC 
presented more anti-apoptotic gene expression 
profiles, and they were more resistant to NK-mediated 
lysis than cells in 2D culture, suggesting an innate 
predisposition to immune escape [179]. Later, MALC of 
RL cell lines were used, by the same authors, to test 
the anti-tumoral activity of obinutuzumab and rituximab, 
two antibodies recently proposed in lymphoma therapy 
[181]. As already demonstrated in several tumor types, 
the cells grown in a 3D model showed different drug 
responses than those grown in 2D, highlighting the 
importance of developing 3D models for the testing of 
chemotherapeutic drugs, not only in NHL, but also in all 
type of cancers. 
5.2.2. Lymphoma Cell Lines on 3D Scaffolds 
Birgersdotter and collaborators [182] developed a 
3D model of HL by using a cell culture matrix based on 
an oligopeptide, which has been extensively tested for 
3D mammalian cell culture [183, 184]. This oligopep-
tide consists of regular repeats of alternating ionic 
hydrophilic and hydrophobic amino acids (arginine, 
aspartic acid and alanine), and associates to form 
stable beta-sheet structures in water. The presence of 
monovalent cations results in the spontaneous 
assembly of the oligopeptide into a stable, macroscopic 
membranous matrix, composed of ordered filaments 
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that form porous enclosures. The authors cultured the 
HL cell line L1236 in the 3D oligopeptide and its gene 
expression profile was analyzed, in parallel with 2D 
culture condition and with fresh lymph node biopsies 
from HL patients. The authors found that the 3D culture 
modulated gene expression of the L1236 cell line, 
better mimicking the in vivo expression profile [182]. 
5.2.3. Co-Cultures of Lymphoma and Stromal Cell 
Lines on 3D Scaffold 
Caicedo-Carvajal and coworkers [175] have deve-
loped a 3D cell co-culture system in order to optimize 
the growth of mantle cell lymphoma (MCL) cell lines. 
The scaffold was made of four layers of polystyrene 
(PS), a geometry generating a characteristic 3D porous 
structure. 3D PS Scaffold was seeded with a MCL cell 
line: HBL2, of lymph node origin. HBL2 cells were co-
cultured with human dermal fibroblasts (hDFb) in the 
3D milieu, showing and enhanced cell proliferation, 
with respect to the 2D culture. The authors suggest that 
this 3D system allows the expansion of primary tumor 
cells of patients, from blood or other tissues in which 
hematological cancer cells are present, and that these 
expanded cells can be used for customized drug 
screening assays.  
6. CNS PEDIATRIC TUMORS 
The heterogeneous group of pediatric CNS tumors 
are the most common solid cancer in the pediatric age 
and the second most common tumor after leukemias, 
representing 20 to 25% of all childhood cancers [12]. 
Pediatric CNS cancers comprise a diverse group of 
tumors with different histology, arising at various sites 
within the central nervous system. The largest 
subgroups are astrocytomas (43% of all brain and CNS 
tumors in children), which are diagnosed throughout 
childhood. Most of the astrocytomas are diagnosed as 
low-grade (grade I: juvenile pilocytic astrocytomas, 
grade II: diffuse astrocytomas), while a small percent-
age as high-grade (grade III: anaplastic astrocytomas 
and grade IV: glioblastoma multiforme). The second 
most common group is represented by the embryonal 
tumors (19% of all childhood brain and CNS tumors). 
Most of these are medulloblastomas and cerebral 
primitive neuroectodermal tumors (PNET). Finally, 
about 10% of childhood brain and CNS tumors are 
ependymomas and choroid plexus tumors [12, 185]. 
6.1. CNS Pediatric Tumor Microenvironment 
High-grade brain tumors display striking cellular 
heterogeneity. Some of the cells show increased 
tumorigenicity and stem-cell-like capacity, and they 
have been proposed as the cells of origin for tumor 
recurrence. Thus, the existence of cancer stem cells 
(CSCs) has been demonstrated in several high-grade 
CNS tumors, such as glioblastomas, ependymomas 
and medulloblastomas, even if the CSCs presence in 
lower grade tumor is controversial [186, 187]. However, 
also in CSN cancer, the tumor-associated parenchymal 
cells, such as endothelial cells, microglia, immune cells 
and neural precursor cells, also play an important role 
in the evolution of the disease.  
Resident activated microglia or new recruited 
macrophages from blood, are the most abundant 
nontransformed cells present in brain tumors. It has 
been shown that the M1 phenotype, with anti-tumoral 
properties, is the most prevalent in low-grade CNS 
tumors, while the M2 phenotype, also designed as 
Tumor Associated Macrophages (TAMs) positively 
correlates with the histological malignancy of the tumor 
[188, 189]. It has been demonstrated that TAMs 
promote glioma cell proliferation, as well as 
angiogenesis and invasion [190, 191]. 
CD8 and CD4 T cells are also present in brain 
tumors. Some authors identified the CD8/CD4 T cell 
ratio as prognostic factors, as demonstrated in non 
CNS tumor. Indeed, in colon cancer it has been 
demonstrated that the CD8/CD4 ratio is higher in 
patients with better clinical outcomes [192]. Consistent 
with these findings, it has been shown that pilocytic 
astrocytomas showed the highest CD8/CD4 ratio and 
that the average ratio of CD8/CD4 in ependymomas, 
multiforme glioblastomas, medulloblastomas was 
progressively lower [188]. However, the correlation 
between lymphocyte infiltration and clinical outcome is 
still controversial.  
More recently, the focus is shifting on the regulatory 
T cells (Tregs), identified by the antigen FoxP3, with 
pro-tumoral activities. For instance, it was shown that 
FoxP3 expression correlates with the tumoral 
progression in several types of astrocytomas [193], and 
that temozolomide, the standard chemotherapeutic 
agent for glioblastoma, induced a reduction of Tregs, 
both in the blood and in the tumor tissues [194]. 
Therefore, Tregs have been identified as a novel 
targets in glioma treatment.  
Recently it has been demonstrated that 
glioblastomas can interact with normal neural precursor 
cells (NPCs). Interestingly, NPCs are recruited from 
brain tumor tissue, thanks to chemoattractant 
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molecules, such as CXCR4, and their number inversely 
correlates with tumor-size and survival. Thus, an 
antitumorigenic action for NCPs has been postulated. 
In vitro experiments seem to sustain this hypothesis, 
since cultured NPCs release soluble factors that can 
inhibit glioblastoma proliferation, induce differentiation 
and cell death [189]. Brain tumors are highly 
vascularised and this rich vascular network is not only 
a matter of tissue oxygenation, but, more importantly, 
of endothelial cells, pericyte, and astrocyte (the 
neurovascular system) presence, that support tumor 
progression. This microanatomical structure, designed 
as perivascular niche (PVN), contain stem cells in both 
normal and brain tumoral tissues. This complex 
network of cells allows multiple interactions, promoting 
CSCs proliferation, enhancing their survival, and 
protecting them from chemotherapy [187, 189]. 
Together with the perivascular niche, it has also 
been postulated the presence of the hypoxic niche 
[186], as already observed in leukemia and other 
tumors. Hypoxia promotes the acquisition of stem-like 
properties, can facilitate the CSCs maintenance, and 
promotes neoangiogenesis [186, 187]. Of note, we 
must not forget the role of ECM in the pathogenesis of 
brain tumoral disease. For instance, it has been 
demonstrated that proteoglycan expression is altered in 
human glioblastoma and that this modification 
promotes an abnormal activation of the receptor 
tyrosine kinase (RTK), involved in the progression of 
the disease [195].  
6.2. 3D Models For CNS Pediatric Tumors 
6.2.1. Tumor Brain Spheroids or Neurospheres 
Spheroids of brain tumor cells (neurospheres) have 
been largely employed by scientists for at least three 
decades. Both stabilized brain cancer cell lines and 
primary cells, obtained from biopsy of CSN tumors, can 
be used to form spheroids [196]. As frequently happens 
in the 3D world, neurospheres are more representative 
of the tumor with respect to the corresponding 
monolayer cultures. For instance, it has been 
demonstrated that genomic profiles of primary cells of 
glioblastomas, cultured in 2D stardard condition, very 
often deviate from the parental cancer profiles, 
whereas genomic profiles are generally preserved in 
sheroids [197]. As with other types of solid tumors, 
neurospheres are also widely used for tumor biology or 
drug screening studies, being suitable for tests on 
proliferation, cell death, invasion and motility [198]. 
After the discovery of neural stem cells [199], research 
on neurospheres has undergone a major impetus. 
Indeed, neurosphere cultures have shown to be a 
suitable method to isolate and propagate neural stem 
cells. The neurosphere assay, developed with the aim 
of confirming that neurospheres contain neural stem 
cells, was initially proposed by Reynolds and Weiss in 
1992 [200]. They were able to culture primary cells 
isolated from the normal striatum tissue of the adult 
mouse brain, in the presence of epidermal growth 
factor. At the beginning of the culture, most of the cells 
had died, but few cells survived, proliferated and 
formed a free-floating 3D spherical cluster of detached 
cells, the neurospheres. The proliferating cells initially 
expressed characteristic markers of stem cells, such as 
nestin. Moreover, the neurospheres continued to 
proliferate in secondary cultures, after their mechanical 
dissociation and plating as single cells. Interestingly, 
after several days of culture, the secondary 
neurospheres were able to differentiate into astrocytes, 
neurons and oligodendrocytes with phenotypes 
characteristic of the adult striatum in vivo [200, 201]. In 
the following years, scientists have demonstrated the 
presence of neural stem cells in several regions of 
embryonic and adult brains both in human and mouse 
[201]. The neurosphere assay is now a widely used 
technique suitable to isolate neural stem cells; it per-
mits to examine the three fundamental characteristics 
of neural stem cells: proliferation, self-renewal, and 
multipotency [201]. Later, neurospheres containing 
stem-like neural precursors were also obtained from 
human glioblastoma multiforme specimens by Galli and 
collaborators [202]. The authors demonstrated the 
ability to proliferate, to undergo self-renewal and to 
generate neurons, astrocytes, and oligodendrocytes, 
as the normal neuronal stem cells do. Moreover, these 
cells injected orthotopically in immunocompromised 
mice can form cancers with a histological architecture 
similar to that of the human tumor [202]. In subsequent 
years, scientists have succeeded in obtaining 
neurospheres containing cancer stem cells from 
ependymomas, medulloblastomas, and primitive 
neuroectodermal tumors and from high grade gliomas 
(grade III anaplastic astrocytomas and grade IV 
glioblastomas) but not from lower grade gliomas [203-
206]. Detailed protocols for obtaining them are now 
available in the literature [200, 204, 207-209]. Thus, the 
neurosphere cultures have represented a suitable 3D 
model for deepening understanding of the role of brain 
tumor stem cells in radio- and chemoresistance 
mechanisms, as well as in the brain tumor response to 
growth factors, hypoxia, and pharmacological agents 
[210-214]. The possibility of performing gene/protein 
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expression analysis as well as to section neurospheres 
for histology or immunocytochemistry allows detailed 
molecular studies. Moreover, the isolation and propa-
gation of neuronal stem cells from a specific specimen 
allows studying patient-specific pharmacologic 
approaches. 
6.2.2. Co-Culturing Neurospheres and Immune 
Cells 
Co-culturing approaches with neurospheres and 
immune cells, normal constituents of the tumor 
microenvironment, are also of particular interest. 
Iwasaki and collaborators studied the infiltrative 
capacity and the cytolytic process of lymphokine-
activated killer (LAK) cells against a human glioma 
spheroid model. Multicellular tumor spheroids were co-
cultured with LAK cells on a rotary shaker. Histological 
analysis revealed that LAK cells are able to infiltrate 
directly in the core of the spheroids, causing tumor 
cytolysis [215].  
Kees and collaborators have studied the role of 
microglia, isolated from patients with glioma, in the 
control of proliferation and invasion of spheroids 
derived from glioblastoma cell lines. They have used a 
collagen co-culture model, seeding both glioma 
spheroids and microglia cells. They demonstrated that 
human microglia has tumor-promoting activities that 
are overridden by pharmacological treatments [216].  
More interestingly, the pro-tumoral effects of the 
altered microglia from brain tumor patients on brain 
tumor initiating cells (BTICs), a subpopulation 
expressing stem cell markers, can be reversed after 
the treatment with Amphotericin B (AmpB). Indeed, 
cultures of monocytes and microglia from glioma 
patients were not able in inhibiting the spheres 
formation of autologous BTICs, but this was modified 
by AmpB treatment [217]. 
In a recent paper, Etminan and co-worker have co-
cultured glioma spheroids with dendritic cells (DCs), 
with the aim of testing the antitumoral efficacy of the 
photodynamic therapy. Indeed, after the treatment, 
immature DCs were recruited into the glioma 
spheroids. They then matured, likely activating specific 
T cells with anti-tumoral activity [218]. 
6.2.3. 3D Co-Cultures of Tumoral CNS Cells and 
Normal Brain Cells 
3D co-cultures of normal brain cells and 
glioblastoma-derived cells have been set up by Biggs 
and coworkers [219]. Normal brain cells were isolated 
from cortices of Wistar rats and allowed to re-
aggregate and to mature for 20 days, by placing them 
on a semi-porous membrane at an air-liquid interface, 
and subsequently generating characteristic brain Hi-
Spots [220, 221]. Histological analysis showed that 
both neurons and astrocytes were present in these 3D 
cultures, with a preserved physiological architecture. 
On this reconstructed 3D neural tissue, fluorescent 
marked glioblastoma cells were seeded. The authors 
could observe their spread throughout the Hi-Spots, 
forming new cell aggregates, and able to last for many 
days (25 d) in culture. This platform was then tested for 
evaluating anticancer compounds, thus representing a 
simple system to verify drug effectiveness on brain 
tumors in an orthotopic environment [219]. 
Orthotopic 3D co-cultures of tumor brain spheroids 
in normal brain tissues have been also set up to test 
invasiveness. In this case neurospheres have been 
implanted on the center of human [133] or rat brain 
slices [222]. The histological evaluation of the 
confrontation revealed either an invasive pattern or a 
non-invasive pattern (see the relevant paragraph for a 
better description). 
6.2.4. 3D Tumoral CNS Cultures on Scaffolds 
One of the earlier research studies on 3D culture of 
brain tumor cells was presented in 1977 by Carllson 
[223]. He studied the mitotic activity of glioma cells 
embedded in an agarose gel, in relation to the position 
of the cells in the colony, finding that the fraction of 
cells that incorporated tritiated thymidine decreased 
nearly exponentially with the depth in the colonies 
[223]. Over time, it has become increasingly clear that 
matrices in which cells are embedded is not simply a 
scaffold to hold them on, but a it is communicating 
structure important in determining cell function and 
behaviour [224]. 
Thus, scientists have tried to mimic specific 
components of the brain ECM, in order to better 
reproduce the microenvironment. Many compositions 
of the matrix have been studied. One of the widely 
used constituents is the collagen [225-227], eventually 
mixed with other molecules, such as agarose [228], the 
ECM proteins tenascin [229] or chondroitin sulfate 
[230]. Among the ECM components, an important role 
has been demonstrated for HA, able to regulate the 
glioma cell phenotype [231] or to increase stem-like 
properties of glioblastoma cells [232]. For this reason, 
hydrogels containing HA have been proposed as a 
scaffold for neuronal tumors [233]. 
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In the recent years, scientists have set up HA-based 
scaffolds in combination with other molecules, such as 
a different type of collagens [230, 234], the kappa-
elastin (HA-?E), present in the basement membrane of 
blood vessels [235], gelatine, PEG [231], and chitosan 
[232]. Besides these natural extracellular matrix 
materials, which are expensive and potentially could 
transmit pathogens [236], several natural polymers 
have been also studied, such as chitosan-alginate 
scaffold [125], or alginate hydrogel functionalized with 
D- or L-aminoacids [237]. Thus, thanks to these 
experimental models it was possible to study the 
impact of the individual components of the ECM on 
tumor biology [230-232] and to assess pre-clinical drug 
and radiation sensitivity screening [238, 239]. 
6.2.5. 3D Models for Testing Motility/Invasion of 
CNS Tumors 
Gliomas are highly infiltrative tumors, thus several 
3D culture methods have been set up in order to study 
this parameter. The widely used 3D transwell or 
spheroid invasion/motility assays in soft matrices, like 
collagen, Matrigel
TM
, fibronectin or agar are extensively 
applied in brain tumor research [225, 226, 240-244]. 
Moreover, several other matrix compositions have 
been tested with the aim of better reproducing the in 
vivo microenvironment. Thus, invasion assays have 
been performed in HA-based hydrogel [230, 233-235].  
An intense interstitial fluid flow is present in gliomas, 
during the processes of angiogenesis, and invasion. 
Therefore, the impact of the interstitial fluid flow on 
glioma cell invasion can be of interest. With this 
purpose, modifications of the classical 3D transwell 
invasion assay have been presented recently [245]. 
Glioma cells, with different invasive properties 
(noninvasive and invasive) were seeded in a gel 
containing HA or collagen I and placed on porous 
membrane, like a classical transwell assay. The above 
setup was modified, by establishing, in the casted gel 
containing the seeded glioma cells, a fluidic flow with 
an average speed of 0.7 μm/s through the cell/gel 
compartment, mimicking the interstitial fluidic flow. 
Interestingly, the authors showed that the interstitial 
flow promotes cell invasion in several glioma cell lines 
and that the flow effect was dependent on the CXCR4 
receptor, involved in brain cancer invasion and 
progression [246]. 
Invasion assays with spheroid co-cultures 
(confrontation assays) has also been developed. In this 
case, neurospheres are placed in contact with normal  
 
tissues, which are used as the target tissues that may 
be invaded and destroyed by invading neoplastic cells 
[247]. Either embryonic chick tissue, foetal brain 
aggregate (heterologous), or normal connective tissue 
from the tumor-bearing patient (autologous) [240, 242, 
248-251] have been used as the target tissues. 
After adhesion of the tumor cells to the normal 
tissue, histological evaluation of the confrontation will 
reveal either an invasive pattern or a non-invasive 
pattern. In the invasive pattern, the tumor-derived cells 
invade into the host tissue and replace it, as it is often 
seen with high grade gliomas [252, 253]. In the non-
invasive pattern the tumor-derived cells live together 
with, and generally surround the host tissue without 
replacing or destroying it, as seen with non-invasive 
benign meningioma [253, 254]. Several upgraded 
protocols have been proposed, which consist in 
implanting fluorescent stained spheroids, obtained from 
human brain tumors, on the center of human [133], or 
rat brain slices [222]. The invasion process can be 
evaluated over the time by using a confocal 
microscopy. The advantages consist in a better 
representation of the invasion process, due to the 
fluorescent tag applied to the tumor cells, as well as in 
a better representation of extracellular matrix 
molecules normally encountered by invading glioma 
cells [133, 222]. Oellers and collaborators described a 
similar refined protocol [255], presenting a co-culture of 
glioma cells with myelinated axons in vitro, with the aim 
to study the interactions between migrating glioma cells 
and nerve fibers. Glioma cells were positioned close to 
the long retinal axons obtained derived from explants of 
embryonic chickens. Migration of cancer cells has been 
monitored by confocal microscopy and high-resolution 
video microscopy [255]. Overall, the invasiveness 
results obtained by confrontation assay are correlated 
with malignancy in vivo [256]. Moreover, this assay is 
also suitable for study of the involvement of specific 
genes, for testing various anti-tumoral molecules/drugs 
or the effect of radiotherapy on brain tumor invasion 
ability [250, 257, 258]. 
Besides these classical assays, scientists have also 
proposed particular protocols to measure motility and 
migration in brain tumors. For instance, Agudelo-Gracia 
and collaborators have studied motility of glioma cells 
cultured on nanofiber scaffolds, that mimic the neural 
topography [259]. Neurospheres obtained form 
glioblastoma cell lines or tumor explants were manually 
placed within nanofiber-coated wells to analyze the 
migration, by analyzing the total area and perimeter  
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covered by the migratory cells. The authors found that 
cell migration of glioblastoma neurospheres was 
reduced by STAT3 inhibitors. Notably, these inhibitors 
at the same concentrations failed to inhibit migration in 
a standard 2D system [259]. 
6.2.6. Bioreactors 
One of the first experiments on brain tumor cells 3D 
growing in a bioreactor was presented by Ingram and 
collaborators [260]. Several malignant glioma cell lines 
were introduced in the NASA rotary cell culture system, 
forming spheroids with an increasing expression of the 
adhesion molecule CD44 over the time in culture [260]. 
An exhaustive study on brain tumor aggregates 
generated using the 3D RCCS
TM
 has been presented 
recently by Smith and collaborators [261]. Several 
types of brain cancer cell lines (pediatric glioblastomas 
and high grade gliomas, pediatric central nervous 
system primitive neuroectodermal tumor, pediatric 
medulloblastomas) were grown in conventional 2D 
cultures and the RCCS
TM
. Gene expression and 
microRNA profiles were analyzed, as well as drug 
sensitivity to Vorinostat, a histone deacetylase inhibitor. 
The principal finding was that 3D culture in RCCS
TM
 
better recapitulates the histological architecture and the 
molecular profiles of primary brain tumors with respect 
to 2D cell culture. Similar findings were also obtained 
with primary explant culture in the RCCS
TM
, which 
retains features of the primary brain tumor. Moreover, 
the 3D glioblastoma aggregated of the RCCS
TM
 
cultures demonstrated a reduced sensitivity to 
Vorinostat with respect to the 2D system, and likely 
better recapitulate the drug response observed in vivo 
[261]. 
Panchalingam and coworkers [262] developed 
bioreactor protocols for expanding cancer stem cells 
from human glioblastoma specimens. Human 
glioblastoma-derived cells were introduced in a 
bioreactor with paddle impellers (NDS Technologies, 
Palo Alto, CA). The expanded cells were characterized 
using both flow cytometry and a differentiation assay. 
The obtained results showed that a high percentage of 
the expanded tumor cells possessed stem cell features 
and that the expression profile was preserved with 
respect to the brain cancer tissue of origin. 
Of note, glioma rat cells have been expanded in 
hollow-fiber bioreactors. However this model system 
was not set up for brain cancer studies but for 
monitoring the cellular effect during ischemia. 
6.2.7. Microfluidic System 
In the literature, there are very few examples of 
studies carried out in microfluidic on 3D brain tumors. 
One of the few studies was presented by Lee and 
collaborators [264], which studied glioma cell migration 
in soft matrices. As in the static cell growth conditions, 
the choice of the matrix is also a crucial point for 
getting the best biomimetic microenvironment in this 
device. These authors have used a HA hydrogel to 
seed the glioma cell line A-172. The HA hydrogel can 
be remodelled by MMPs secreted by glioma cells 
during migration, and the authors have studied the 
concentration gradient effect of VEGF in this 
parameter. The authors observed an intense spreading 
of glioma cells in the microchannel containing VEGF; 
moreover these cells were more able to degrade MMP-
sensitive hydrogel with respect to control cells [264]. 
A second type of study in microfluidics, which 
preserves the 3D cell structure, are those dealing with 
brain slices. The microfluidic technology seems to 
better preserve the viability of the explanted tissues for 
some days, by improving the oxygen/nutrient 
penetration into slices. Therefore, this device can be of 
interest for developing personalized cancer therapies 
[265, 266]. 
An interesting microfluidic experimental model was 
proposed by Ma and collaborators [267]. They tested 
the cytotoxicity of two anticancer drugs, temozolomide 
(TMZ) and ifosfamide (IFO), on glioblastoma 
multiforme brain cancer cells in conjunction with liver 
metabolism. The microfluidic devices contained two 
separate chambers connected in tandem, one for 
seeding liver cells with different cytochrome P450 
(CYP) subtypes and the second for seeding tumor 
brain cells. Both chambers contained polylactic acid 
(PLA) as a scaffold, to allow the 3D culture. TMZ, 
which is inactivated by liver metabolism, was more 
ineffective in the presence of 3D liver cultures. 
Conversely, ifosfamide (IFO), which requires CYP-
dependent activation for its antitumor activity, showed 
the maximum cytotoxicity in the presence of CYP 
overexpressing liver cells. Thus, this model could better 
predict drug effects, by considering the contribution of 
liver metabolism on drug activities [267]. 
The limited production on microfluidic devices 
applied to 3D cellular models might suggest, on one 
hand, that there are technical difficulties occurring, and, 
on the other hand, that scientists may prefer different  
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3D models. Indeed, 3D models permit the culture of a 
higher number of cells, and they are not subject to 
potential biological artifacts, due to mechanical stress 
for the high hydrodynamic shear forces [268]. 
6.2.8. Brain Tumor Explants of Surgical Specimens 
The cultivation of tumor explants allows the 
maximum preservation of the microenvironment and in 
personalizing the culture. Of course, they have limited 
survival time and scientists are committed to finding 
new protocols to lengthen this time. Some tissues are 
more suitable, such as lung and colon [269], 
unfortunately, ex vivo cultures of brain tumor tissues 
are more difficult to obtain, because of their friability. 
Tumor blocks transferred in culture medium can be 
maintained up to 48 hours with preserved 
histoarchitecture of glioblastoma. In contrast, starting 
from 72 hours, tumor tissues present cells in apoptosis 
[270]. Few attempts have been made to lengthen the 
time of vitality in culture of brain tumor explants, such 
as those performed in microfluidic devices or in 
bioreactors (see the relevant paragraphs). 
7. NEUROBLASTOMA 
Neuroblastoma (NBL) is the most frequent 
extracranial solid tumor of childhood, occurring in very 
young children, as the median age at diagnosis is 17 
months [271]. NBL present a large number of clinical 
manifestations that range from spontaneous regression 
to very aggressive malignant growth, so that NBL 
disease is classified into low-, intermediate-, or high-
risk categories, based upon clinical and biological 
features. The accurate stage of patients at diagnosis 
and the classification on risk groups is important to 
tailor the therapy, in order to reduce toxicity and 
improve outcomes. NBL accounts for about 7% all 
childhood neoplasms, but it is responsible for 10% for 
the deaths from pediatric malignant diseases [272]. 
One of the most important prognostic factors is age, 
with an inverse relationship between age and outcome. 
Other prognostic factors are the presence of 
metastasis and some genetic factors of the tumor as 
MYCN amplification, 11q deletion and structural 
aberrations [271, 272]. Tyrosine kinases -TRK family of 
neurotrophin receptors greatly correlates with clinical 
outcomes: TrkA expression is associated with a 
favorable clinical behavior, whereas TrkB with 
unfavourable outcome [273]. For babies aged younger 
than 18 months without the amplification of MYCN, 
even those with metastases, prognosis is better than 
for older children [271]. 
Neuroblastomas originate from primordial neural 
crest cells, thus tumors occur mostly in the adrenal 
medulla and the rest arise anywhere along the chain of 
the sympathetic nervous system. They can present as 
mass lesions in the chest, neck, pelvis or abdomen. 
Almost 50% of the patients have metastatic disease at 
diagnosis, especially in liver, skin, lung, BM and bone 
[271]. 
7.1. Neuroblastoma Microenvironment 
The tumor microenvironment strongly contributes to 
the evolution of NBL disease. One of the most explored 
components of the NBL microenvironment is the 
immune system. It is well-known that high risk NBL can 
escape the immune system [274]. Several mechanisms 
have been proposed, such as the downregulation of 
the human leukocyte antigen (HLA) or adhesion 
molecule expression on the surface of NBL cells, and 
the expression of chemokines by tumor cells or 
infiltrating stromal cells that can down-modulate 
immune responses or recruit macrophages to disable 
these lymphocytes [275]. 
Targeting immune cells, modulating surface 
molecules involved in the immuno-response, interfering 
with the cytokine activities, all are promising therapies 
in fighting this disease [275-277]. Other studies have 
pointed out the importance of hypoxia level in the 
progression of the disease. Indeed, it has been 
demonstrated that the adaptation to low tension of 
oxygen induces the expression of several genes (the 
‘hypoxia gene signature’), which allows the cells to 
survive. Moreover, during hypoxia, NBL cells are more 
resistant to apoptosis, leading to pleiotropic drug-
resistance [278, 279]. 
Profiling several tumor specimens of neuroblastoma 
patients, Fardin and coworkers [280] have found that 
the hypoxia gene signature is associated with most 
aggressive subtypes, without regard to the MYCN 
amplification. These authors have proposed that the 
hypoxia gene signature can be a new potential 
prognostic factor for neuroblastoma.  
The angiogenic switch, intimately correlated with the 
hypoxic condition [281], is also involved in NBL 
progression. Indeed, it has been demonstrated that 
several angiogenic factors, such as VEGF, are 
expressed in NBL tissues in vivo; moreover, a positive 
correlation was observed between VEGF expression 
and poor outcome [282]. 
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Relapse and metastases constitute the major 
challenges in clinical management of NBL. Tumor cells 
disseminating from primary sites to various organ sites 
have several possible fates: death, progression toward 
metastasis or formation of dormant micrometastasis. 
Dormant micrometastasis could progress to an actively 
growing macrometastatic lesion and cause a late 
metastatic relapse in the high risk group of NBL 
patients [283]. Thus, specific microenvironment factors 
involved in the progression of micrometastasis or in the 
attraction of human neuroblastoma cells in the site of 
metastasis have been studied in several organs, such 
as lung [284], bone [285, 286] or BM [287]. 
7.2. 3D Models for Neuroblastoma 
7.2.1. Neuroblastoma Spheroids  
The NBL spheroids have been used for more than 
two decades. As demonstrated in other types of 
tumors, NBL spheroids better recapitulate the salient 
aspects of in vivo neoplasm growth [288, 289]. For 
instance, Kumar and coworkers [288] have studied the 
different protein expression profile when NBL cells are 
cultured in 2D with respect to 3D. The proteomic 
analysis was performed by 2D gel electrophoresis and 
followed by mass spectrometry identification. Several 
polypeptides involved in metabolism, cell structure, cell 
stress response, signal transduction and transport were 
over-expressed in NBL spheroids. The differential 
proteins identified suggest that NBL spheroids better 
recapitulate in vivo tumor physiology. 
The main fields of application of NBL spheroids are 
studies on drug discovery [290], radiosensitivity/ 
radioresistance [291], targeted radiotherapy [292], new 
therapeutic strategies [293] or mechanisms of tumor 
initiation and progression [294]. 
Neuroblastoma cell lines are also used as a model 
for neurodegenerative diseases, due their ability to 
differentiate into neuronal like cells. Indeed, it is well 
established that the 2D cultured human NBL cell line 
SH-SY5Y [295] can be differentiated into several neural 
cell phenotypes using agents such as retinoic acid (RA) 
[296] or brain-derived neurotrophic factor (BDNF) [297]. 
The use of neuroblastoma SH-SY5Y spheroid 
cultures further improved the model of neuronal 
differentiated tissues. Jung and coworkers [289] have 
evaluated the differentiating action of RA on SH-SY5Y 
spheroids. They showed that the expression of 
neuronal markers (synaptophysin, neuron-specific 
enolase- NSE), the contents of cell adhesion molecules 
and ECM proteins, and the ability to extend neurites 
were much higher in RA-treated spheroids than in RA-
treated monolayer cells [289]. Interestingly, Seidel and 
collaborators [298] succeeded in differentiating SH-
SY5Y spheroids without the need of differentiation 
promoting agents, by cultivating them in a gyratory 
shaker. This neuronal 3D-culture model was then used 
to study the contribution of the protein TAU in the 
neurodegenerative processes. 
7.2.2. 3D Invasion Assays  
Invasiveness is an important feature of all 
metastatic tumors, so that invasion assays are widely 
used tools in neuroblastoma research. In 3D 
conditions, Matrigel
TM
 invasion chamber assay is one 
of the most popular method [299-305], together with 
the invasion assays through 3D collagen gels [306]. 
Thanks to these studies, the effects of ionizing 
radiation [307], differentiating agents [299, 301], 
antitumoral drugs/molecules [303-305] or the 
contribution of specific oncogenes [300, 302] on 
invasiveness have been explored. 
7.2.3. NBL Cells on Scaffolds 
Neuroblastoma 3D culture embedded in soft 
matrices, like agarose, Matrigel
TM
 or collagen, is widely 
used by scientists [299-305, 308]. Valero and 
coworkers [309], have studied the impact of different 
soft matrices on neuronal differentiation of the Neuro2a 
neuroblastoma cell line (N2a), evaluated with a novel 
impedimetric biosensor. The authors showed that 
neither agarose nor bare collagen was able to support 
the differentiation of N2a cells. On the contrary, 
collagen-laminin mixture was able to do it by promoting 
the appearance of long neurites, touching the adjacent 
neurons. 
Besides the common matrices, new biomolecules 
have been explored, such as the bacterial nano-
cellulose, excreted by Gluconacetobacter xylinus [310], 
or synthesized materials such as poly (L-lactic acid) 
PLL [311], photocurable polylactide (PLA) resin [312], 
poly(DL-lactide-co-glycolide) acid [313], carbon 
structures [314] or polymeric microspheres [315]. 
However, the main applicative field, by using these new 
materials, is not the NBL cancer research, but the 
neural tissue engineering, thanks to the properties of 
NBL cells to form neuron-like tissues.  
7.2.4. Bioreactors 
Literature is poor regarding papers presenting data 
obtained with bioreactors in the NBL cancer research 
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field. However, the application potential of this 
experimental model is interesting, as suggested by 
Redder and coworkers [316, 317]. These authors have 
demonstrated that the study in the microgravity rotary 
bioreactors of the cellular in vitro aggregation kinetics 
and organoid morphology correlate to the neuro-
blastoma malignant potential. Amplified- MYCN or TrkB 
expressing neuroblastoma cell lines, with unfavorable 
outcomes, aggregated much more rapidly than 
unamplified MYCN or TrkA expressing neuroblastoma 
cell lines. Moreover, the authors observed differences 
in organoid morphology between the two groups. The 
authors then proposed the microgravity assay as a 
rapid and reproducible in vitro assessment of 
neuroblastoma malignant potential. 
By using a rocking bioreactor system, an interesting 
application in NBL medical treatment was proposed by 
Rujkijyanont and coworkers [318]. CD56+ natural killer 
(NK) immune cells isolated from peripheral blood cells 
of normal donors and NBL patients were cultured and 
expanded in the rocking bioreactor. After the culturing, 
expanded CD56+ cells showed a marked increase of 
cytolytic activity on all the NBL cells studied. This 
procedure can represent a new therapeutical strategy 
in order to generate autologous or allogeneic CD56+ 
cells able to kill NBL cells but with a low risk of Graft 
versus Host Disease- GVHD.  
CLOSING REMARKS 
Since the 1980s, 3D culture has known a great 
evolution, that completely refined the scientific 
approach to cancer biology. The “third” dimension 
provided to in vitro cultured cells a new context, 
favoring normal and cancer cells/matrix interactions 
and cross-talk, thus mimicking, in a more natural way, 
the tumor microenvironment. This cancer hallmark 
plays a crucial function in regulating tumor behavior 
and survival, but it still needs to be better understood in 
order to be used in targeted cancer therapy. The 3D 
cell culture is a potent tool to model normal and 
pathological tissues, in order to increase our basic 
knowledge in tumor evolution (initiation, progression 
and invasion), as well as to better target oncological 
therapy.  
However, even if great scientific and technical 
efforts have been made, there is not yet, at present, the 
perfect in vitro model able to exactly mimic tumor cells 
and its microenvironment, as it exists in the patient. As 
indicated by the literature, several 3D culture models 
are able optimally to represent many cancer hallmarks 
/outcomes. Nevertheless, none of these models can 
reproduce with accuracy the whole and complex in vivo 
tumor context, even if each one provides valid scientific 
information to assess tumor biology and anti-tumoral 
drugs efficacy/resistance. We still lack the ideal model 
that can be translated from lab benches to preclinical 
trials and to personalised cancer treatment. But the 
questions are: can such a model exist? Can/must a 
singular in vitro model mirror the complexity of a wide 
range of cancers? Can a so complex condition be 
translated into a simplified in vitro/ex vivo system? In 
effect, because our knowledge on cancer(s) is still 
partial, a number of queries are not answered. 
Thus, for the next steps, it is imperative that onco-
logy research includes multidisciplinary competences 
(engineers, physicists, biologists, healthcare doctors, 
oncologists, pharmacologists, toxicologists, etc.), in 
order to better concentrate efforts and define the basic, 
pre-clinical and clinical endpoints, as well as the 
experimental strategies to reach such objectives. 
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